var title_f18_54_19296="Equalization of pressures";
var content_f18_54_19296=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F80355&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F80355&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 481px\">",
"   <div class=\"ttl\">",
"    Equalization of pressures in severe constrictive pericarditis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 461px; height: 163px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Tracing from a patient with severe constrictive pericarditis shows that the wedge and right atrial pressures are equal during inspiration, but that the wedge pressure is higher during expiration.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ralph Shabetai, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_54_19296=[""].join("\n");
var outline_f18_54_19296=null;
var title_f18_54_19297="Pefloxacin: International drug information";
var content_f18_54_19297=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"9\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Pefloxacin: International drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F1979910\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Abaktal (CZ, HR, HU);",
"     </li>",
"     <li>",
"      Azuben (ES);",
"     </li>",
"     <li>",
"      Dital (HR);",
"     </li>",
"     <li>",
"      Ifipef (IN);",
"     </li>",
"     <li>",
"      Niux (AR);",
"     </li>",
"     <li>",
"      Nopriken (MX);",
"     </li>",
"     <li>",
"      Pefbid (IN);",
"     </li>",
"     <li>",
"      Peflacin (BR, DE, HU, IT, NL);",
"     </li>",
"     <li>",
"      Peflacina (AR, MX);",
"     </li>",
"     <li>",
"      Peflacine (AT, BE, BR, CZ, ES, FR, HU, LU, PT);",
"     </li>",
"     <li>",
"      Peflox (IT);",
"     </li>",
"     <li>",
"      Pelox (IN, ZA);",
"     </li>",
"     <li>",
"      Perfloden (ES);",
"     </li>",
"     <li>",
"      Piflasyn (IN);",
"     </li>",
"     <li>",
"      Proflox (IN);",
"     </li>",
"     <li>",
"      Septoper (ES)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list synlist drugH1Div drugBrandNames\" id=\"F1979903\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Index Terms",
"    </span>",
"    <ul>",
"     <li>",
"      Pefloxacin Mesylate Dihydrate",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1979905\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antibiotic, Quinolone",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block iuse drugH1Div\" id=\"F1979908\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reported Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of bacterial infections caused by susceptible strains; use limited to serious infections",
"    </p>",
"   </div>",
"   <div class=\"block idos drugH1Div\" id=\"F1979904\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justified;\">",
"     Oral: 400 mg twice daily; taken with food",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justified;\">",
"     Ophthalmic: 1-2 drops in affected eye(s) 2-6 times/day, depending on severity of infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justified;\">",
"     I.V.: 400 mg twice daily given by slow infusion over 1 hour",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11821082\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Product available in various countries; not currently available in the U.S.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F1979907\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justified;\">",
"     Infusion [premixed]: 400 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justified;\">",
"     Injection, solution: 80 mg/mL (5 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justified;\">",
"     Solution, ophthalmic: 0.3% (5 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justified;\">",
"     Tablet: 400 mg",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10425 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-61.234.146.186-B3512DFB86-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_54_19297=[""].join("\n");
var outline_f18_54_19297=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1979910\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1979903\">",
"      Index Terms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1979905\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1979908\">",
"      Reported Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1979904\">",
"      Dosage Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11821082\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1979907\">",
"      Dosage Forms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10425\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10425|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_54_19298="Skin biopsy discoid SLE";
var content_f18_54_19298=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F81453&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F81453&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Discoid lupus erythematosus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 241px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    An attenuated epidermis is surmounted by an orthohyperkeratotic scale with follicular plugging. An active vacuolopathic interface dermatitis is present.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Cynthia Magro, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_54_19298=[""].join("\n");
var outline_f18_54_19298=null;
var title_f18_54_19299="Obturator fossa nodes";
var content_f18_54_19299=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F62739&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F62739&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Obturator fossa node dissection",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 427px; height: 363px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The lymphatic tissue of the obturator fossa is freed from the lateral pelvic sidewall by bluntly dissecting lateral to the external iliac artery and vein. The obturator nerve is then identified coursing through the obturator fossa and freed of lymphatic tissue by running the Metzenbaum scissors parallel to the nerve. The lymphatic tissue can now be lifted out of the obturator fossa carefully to avoid damaging the internal iliac artery and vein.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of William J Mann, Jr, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_54_19299=[""].join("\n");
var outline_f18_54_19299=null;
var title_f18_54_19300="Acrokeratosis paraneoplastica - multiple sites";
var content_f18_54_19300=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F66781&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F66781&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 540px\">",
"   <div class=\"ttl\">",
"    Acrokeratosis paraneoplastica",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 520px; height: 390px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Erythematous, scaly papules and plaques on finger (A), periungual region (B), right ear (C), and right elbow (D). Arrows point to most involved areas.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Sator, PG, Breier, F, Gschnait, F. Acrokeratosis paraneoplastica (Bazex's syndrome): Association with liposarcoma. J Am Acad Dermatol 2006; 55:1103. Copyright &copy; 2006 The American Academy of Dermatology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_54_19300=[""].join("\n");
var outline_f18_54_19300=null;
var title_f18_54_19301="Apoptotic hepatocyte";
var content_f18_54_19301=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F53654&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F53654&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Acute lobular hepatitis, apoptotic hepatocyte (high power, Masson trichrome)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 335px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Apoptotic hepatocyte (formerly called an \"acidophilic body\" or \"Councilman body\") within the vacuole of an enlarged Kupffer cell. The sinusoid contains many mononuclear inflammatory cells.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Marshall M. Kaplan, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_54_19301=[""].join("\n");
var outline_f18_54_19301=null;
var title_f18_54_19302="Acute tinea pedis";
var content_f18_54_19302=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F54214%7EPC%2F62902&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F54214%7EPC%2F62902&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Acute tinea pedis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 378px; height: 268px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The medial aspect of the left great toe demonstrates erythematous, papulo-vesicular lesions caused by Trichophyton mentagrophytes.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of John T Crissey, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Acute tinea pedis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 290px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Vesicles and bullae are present on the plantar foot in this patient with acute tinea pedis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Goodheart, HP. Goodheart's Photoguide of Common Skin Disorders, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright &copy; 2003 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_54_19302=[""].join("\n");
var outline_f18_54_19302=null;
var title_f18_54_19303="Influenza virus vaccine (live attenuated): Drug information";
var content_f18_54_19303=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"17\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Influenza virus vaccine (live attenuated): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?11/43/11953?source=see_link\">",
"    see \"Influenza virus vaccine (live attenuated): Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?14/10/14502?source=see_link\">",
"    see \"Influenza virus vaccine (live attenuated): Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block spa drugH1Div\" id=\"F14961380\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Special Alerts",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Influenza Virus Vaccine",
"     </span>",
"     <span class=\"collapsible-date\">",
"      2012-2013",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       The 2012-2013 influenza virus vaccine contains the same H1N1 virus as in the 2011-2012 vaccine, but different H3N2 and B viruses. The vaccine strains approved for this season in the United States are as follows: A/California/7/2009 (H1N1)-like virus, A/Victoria/361/2011 (H3N2)-like virus, and B/Wisconsin/1/2010-like virus. Because immunity to influenza virus declines over time, and because two of the three strains of the virus are different this year than last, persons should be vaccinated every year even if vaccinated during the previous season",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       In addition, a variant influenza A virus (H3N2v) is currently circulating in pigs and infecting humans. Immunization with the 2012-2013 seasonal influenza vaccine is not expected to provide protection against this virus.  Symptoms of H3N2v are generally similar to those of seasonal influenza infections.  Unfortunately, standard tests used to detect influenza virus cannot differentiate between H3N2v virus from seasonal influenza A (H3N2) virus and there is a potential for false negatives with antigen detection tests. Clinicians who suspect probable H3N2v virus should contact their local or state health department for additional testing for H3N2v at a state public health laboratory. A link to recent swine exposure (within 1 week) of symptom onset should be considered a probable H3N2v case. Antiviral treatment of H3N2v influenza is the same as seasonal influenza.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       For additional information refer to the following websites:",
"      </p>",
"      <p style=\"text-indent:0em;margin-left:2em;margin-top:0em;\">",
"       FDA approves vaccines for the 2012-2013 influenza season:",
"       <a href=\"file://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm315365.htm\" target=\"_blank\">",
"        file://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm315365.htm",
"       </a>",
"      </p>",
"      <p style=\"text-indent:0em;margin-left:2em;margin-top:0em;\">",
"       CDC, Interim Information about Human Infections with H3N2v Virus:",
"       <a href=\"file://www.cdc.gov/flu/swineflu/h3n2v-clinician.htm\" target=\"_blank\">",
"        file://www.cdc.gov/flu/swineflu/h3n2v-clinician.htm",
"       </a>",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F9560232\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      FluMist&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F11239606\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      FluMist&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F9560235\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Vaccine, Live (Viral)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F9600971\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is important to note that influenza seasons vary in their timing and duration from year to year. In general, vaccination should begin soon after the vaccine becomes available and prior to onset of influenza activity in the community. However, vaccination should continue throughout the influenza season as long as vaccine is available.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Immunization:",
"     </b>",
"     Intranasal (FluMist&reg;):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      U.S. labeling:",
"     </i>",
"     Adults &le;49 years: 0.2 mL/dose (1 dose per season)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Canadian labeling:",
"     </i>",
"     Adults &le;59 years: 0.2 mL/dose (1 dose per season)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F9560248\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?14/10/14502?source=see_link\">",
"      see \"Influenza virus vaccine (live attenuated): Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is important to note that influenza seasons vary in their timing and duration from year to year. In general, vaccination should begin soon after the vaccine becomes available and prior to onset of influenza activity in the community. However, vaccination should continue throughout the influenza season as long as vaccine is available.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Immunization:",
"     </b>",
"     Intranasal:",
"     <i>",
"      FluMist&reg;",
"     </i>",
"     :",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children 2-8 years: 0.2 mL/dose (1 or 2 doses per season; see",
"     <b>",
"      \"Note\"",
"     </b>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &ge;9 years: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     <b>",
"      Note:",
"     </b>",
"     Children 6 months to &lt;9 years who received a total of &ge;2 doses of seasonal influenza vaccine since July 1, 2010, need only 1 dose of the 2012-2013 seasonal influenza vaccine. If a child did not receive a total of &ge;2 doses of seasonal vaccine since July 1, 2010, if they have never received seasonal influenza vaccine, (ie, this is their first season of vaccination), or if their vaccination status cannot be determined, they should receive 2 doses separated by &ge;4 weeks, in order to achieve satisfactory antibody response. Additional dosing considerations are provided when vaccination history is available prior to the 2010-2011 season; see current guidelines for additional information (CDC, 2012).",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F9600972\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not indicated for use in patients &ge;50 years (U.S. labeling) or &ge;60 years (Canadian labeling).",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15897889\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15897890\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F9560249\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, intranasal [spray, preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     FluMist&reg;:  (0.2 mL) [contains arginine, chicken egg protein, gelatin, gentamicin  (may have trace amounts)]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F9560334\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F13845071\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FluMist&reg; Quadrivalent Vaccine: FDA approved February 2012; availability anticipated for the 2013-2014 flu season. Consult prescribing information for additional information.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Seasonal quadrivalent influenza  vaccines contain two subtype A strains and two subtype B strains; trivalent influenza vaccines contain two subtype A strains and one subtype B strain.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F9560338\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     LAIV: Intranasal: Half the dose (0.1 mL) is administered to each nostril; patient should be in upright position. A dose divider clip is provided. Severely immunocompromised persons should not administer the live vaccine. If recipient sneezes following administration, the dose should not be repeated.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Simultaneous administration of vaccines helps ensure the patients will be fully vaccinated by the appropriate age. Simultaneous administration of vaccines is defined as administering &gt;1 vaccine on the same day at different anatomic sites. The ACIP prefers each dose of a specific vaccine in a series come from the same manufacturer when possible. However, in general, vaccination should not be deferred if the brand name or route of the previous dose is not available or not known (CDC, 2011).",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;text-align:justify;\">",
"     Antipyretics have not been shown to prevent febrile seizures. Antipyretics may be used to treat fever or discomfort following vaccination (CDC, 2011). One study reported that routine prophylactic administration of acetaminophen to prevent fever prior to vaccination decreased the immune response of some vaccines; the clinical significance of this reduction in immune response has not been established (Prymula, 2009).",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Vaccine administration with oral influenza antiviral medications:",
"     </b>",
"     Live influenza virus vaccine (LAIV) should not be given until 48 hours after the completion of influenza antiviral therapy (influenza A and B). Influenza antiviral therapy (influenza A and B) should not be administered for 2 weeks after receiving LAIV. If influenza antiviral therapy (influenza A and B) and LAIV are administered concomitantly, revaccination should be considered.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F9560335\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Provide active immunity to influenza virus strains contained in the vaccine",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     The Advisory Committee on Immunization Practices (ACIP) states that healthy, nonpregnant persons aged 2-49 years may receive vaccination with either the seasonal live, attenuated influenza vaccine (LAIV) (nasal spray) or the seasonal trivalent inactivated influenza vaccine (TIV) (injection).",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F9560333\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Influenza virus vaccine may be confused with flumazenil",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F9560239\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      All serious adverse reactions must be reported to the U.S. Department of Health and Human Services (DHHS) Vaccine Adverse Event Reporting System (VAERS) 1-800-822-7967 or online at",
"      <a href=\"https://vaers.hhs.gov/esub/index\" target=\"_blank\">",
"       https://vaers.hhs.gov/esub/index",
"      </a>",
"      .",
"     </b>",
"     In Canada, adverse reactions may be reported to local provincial/territorial health agencies or to the Vaccine Safety Section at Public Health Agency of Canada (1-866-844-0018).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Frequency of events reported within 10 days.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (children 3% to 9%; adults 40%), irritability (children 12% to 21%), lethargy (children 7% to 14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Appetite decreased (children 13% to 21%), abdominal pain (children 2% to 12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Tiredness/weakness (adults 26%), muscle aches (children 2% to 6%; adults 17%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Cough (adults 14%), nasal congestion/ runny nose (children 51% to 58%; adults 9% to 44%), sore throat (children 5% to 11%; adults 28%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Chills (children 2% to 4%, adults 9%), fever (100&deg;F to 101&deg;F: children 6% to 9%; &gt;101&deg;F: children 1% to 4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Otic: Otitis media (children 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Sinusitis (adults 4%), sneezing (children 2%), wheezing (children 6-23 months 6%; children 24-59 months 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Postmarketing and/or case reports: Anaphylactic reactions, asthma exacerbations, Bell's palsy, encephalitis (vaccine associated), epistaxis, Guillain-Barr&eacute; syndrome, hypersensitivity reaction, meningitis (including eosinophilic meningitis), mitochondrial encephalomyopathy (Leigh syndrome) exacerbation, pericarditis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F9560336\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prior life-threatening reaction to previous influenza vaccination; hypersensitivity to any component of the formulation; children 2-17 years of age receiving aspirin therapy",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F9600949\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anaphylactoid/hypersensitivity reactions: Immediate treatment (including epinephrine 1:1000) for anaphylactoid and/or hypersensitivity reactions should be available during vaccine use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Acute illness: May consider deferring administration in patients with moderate or severe acute illness (with or without fever); may administer to patients with mild acute illness (with or without fever).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Asthma/wheezing: The nasal spray should not be used in patients with asthma or children &lt;5 years of age with recurrent wheezing; risk of wheezing following vaccination is increased. Patients with severe asthma or active wheezing were not included in clinical trials. Children &lt;24 months of age had increased wheezing and hospitalizations following administration in clinical trials; use of the nasal spray is not approved in this age group. Because safety and efficacy information is limited, the ACIP does not recommend the use of LAIV in patients with chronic pulmonary disorders including asthma and children 2-4 years of age who have had asthma or wheezing episodes within the past year.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disorders: Because safety and efficacy information is limited, the ACIP does not recommend the use of LAIV in patients with chronic disorders of the cardiovascular system (except isolated hypertension).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Because safety and efficacy information is limited, the ACIP does not recommend the use of LAIV in patients with chronic metabolic diseases including diabetes mellitus.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Guillain-Barr&eacute; syndrome: Use with caution in patients with history of Guillain-Barr&eacute; syndrome (GBS); patients with history of GBS have a greater likelihood of developing GBS than those without. As a precaution, the ACIP recommends that patients with a history of GBS and who are at low risk for severe influenza complications, and patients known to have experienced GBS within 6 weeks following previous vaccination should generally not be vaccinated (consider influenza antiviral chemoprophylaxis in these patients). Based on limited data, the benefits of vaccinating persons with a history of GBS who are also at high risk for complications of influenza, may outweigh the risks.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hematologic disorders: Because safety and efficacy information is limited, the ACIP does not recommend the use of LAIV in patients with hematologic disorders and hemoglobinopathies.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic disease: Because safety and efficacy information is limited, the ACIP does not recommend the use of LAIV in patients with hepatic disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; HIV: HIV: Because the nasal spray contains live, attenuated virus, the ACIP does not recommend the use of LAIV in patients with HIV.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Nasal congestion: Defer immunization if nasal congestion is present which may impede delivery of vaccine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neurologic/neuromuscular disorders: Because safety and efficacy information is limited, the ACIP does not recommend the use of LAIV in patients with neurologic or neuromuscular disorders.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal disease: Because safety and efficacy information is limited, the ACIP does not recommend the use of LAIV in patients with renal disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Vaccines: In order to maximize vaccination rates, the ACIP recommends simultaneous administration of all age-appropriate vaccines (live or inactivated) for which a person is eligible at a single clinic visit, unless contraindications exist.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Adults: The U.S. labeling states that safety and efficacy of the nasal spray have not been established in adults &ge;50 years of age. Use in adults &lt;60 years is approved in the Canadian labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Altered immunocompetence: Data on the use of the nasal spray in immunocompromised patients is limited.",
"     <b>",
"      Avoid contact with severely immunocompromised individuals for at least 7 days following vaccination (at least 14 days per Canadian labeling).",
"     </b>",
"     Because safety and efficacy information is limited, the ACIP does not recommend the use of LAIV in immunosuppressed patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pregnant women: Because safety and efficacy information is limited, the ACIP does not recommend the use of LAIV in pregnant women.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Arginine: Manufactured using arginine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Chicken egg protein: Manufactured with chicken egg protein. Allergy to eggs must be distinguished from allergy to the vaccine. Recommendations are available from the CDC regarding influenza vaccination to persons who report egg allergies; however, a prior severe allergic reaction to influenza vaccine, regardless of the component suspected, is a contraindication to vaccination. Use of TIV is preferred over LAIV when considering vaccination in persons reporting an egg allergy (CDC, 2012).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gelatin: Manufactured using gelatin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gentamicin: Manufactured with gentamicin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Effective immunity: Vaccination may not result in effective immunity in all patients. Response depends upon multiple factors (eg, type of vaccine, age of patient) and may be improved by administering the vaccine at the recommended dose, route, and interval. Vaccines may not be effective if administered during periods of altered immune competence (CDC, 2011).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Previous season vaccines: Influenza vaccines from previous seasons must not be used.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299520\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F9600965\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antiviral Agents (Influenza A and B): May diminish the therapeutic effect of Influenza Virus Vaccine (Live/Attenuated). Management: Avoid anti-influenza antivirals during the period beginning 48 hours prior to and ending 2 weeks after vaccine administration.  Persons receiving these agents within 2 weeks of the live intranasal spray vaccine should receive a repeat vaccine dose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AzaTHIOprine: May enhance the adverse/toxic effect of Vaccines (Live).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Belimumab: May enhance the adverse/toxic effect of Vaccines (Live).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May enhance the adverse/toxic effect of Vaccines (Live).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fingolimod: May enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Fingolimod may diminish the therapeutic effect of Vaccines (Live).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hydroxychloroquine: May enhance the adverse/toxic effect of Vaccines (Live).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Immune Globulins: May diminish the therapeutic effect of Vaccines (Live). Management: Live organism vaccination should be withheld for up to 6 months following immune globulin administration.  Live vaccine given immediately prior to immune globulin may require repeat vaccination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Immunosuppressants: May enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live). Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     AzaTHIOprine; Beclomethasone (Oral Inhalation); Betamethasone; Budesonide (Systemic, Oral Inhalation); Corticotropin; Cortisone; Cytarabine (Liposomal); Dexamethasone (Systemic); Fludrocortisone; Fluticasone (Oral Inhalation); Hydrocortisone (Systemic); Hydroxychloroquine; Leflunomide; Mercaptopurine; Methotrexate; MethylPREDNISolone; PrednisoLONE (Systemic); PredniSONE; Triamcinolone (Systemic).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: May enhance the adverse/toxic effect of Vaccines (Live).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mercaptopurine: May enhance the adverse/toxic effect of Vaccines (Live).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrexate: May enhance the adverse/toxic effect of Vaccines (Live).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: Influenza Virus Vaccine (Live/Attenuated) may enhance the adverse/toxic effect of Salicylates. Specifically, Reye's syndrome may develop.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tuberculin Tests: Vaccines (Live) may diminish the diagnostic effect of Tuberculin Tests.  Management: If a parenteral live vaccine has been recently administered, a scheduled PPD skin test should not be administered for at least 4-6 weeks following the administration of the vaccine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F9600944\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F9600945\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were not observed in animal reproduction studies. LAIV is not recommended for use during pregnancy. Influenza vaccination with the trivalent inactivated vaccine (TIV) is recommended for all women who are or will become pregnant during the influenza season and who do not otherwise have contraindications to the vaccine.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Healthy pregnant women do not need to avoid contact with persons vaccinated with LAIV and pregnant healthcare providers may administer the LAIV. The nasal vaccine contains the same strains of influenza A and B found in the injection. Information specific to the use of LAIV in pregnancy has not been located. Refer to the Influenza Virus Vaccine (Inactivated) monograph for additional information.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Healthcare providers are encouraged to refer women exposed to the influenza vaccine during pregnancy to the Vaccines and Medications in Pregnancy Surveillance System (VAMPSS) by contacting The Organization of Teratology Information Specialists (OTIS) at (877) 311-8972.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F9600947\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F9600948\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The use of LAIV should be used with caution in breast-feeding women (per manufacturer) due to the possibility of virus excretion into breast milk. However breast-feeding is not a contraindication to vaccination and LAIV may be administered to breast-feeding women unless contraindicated due to other reasons (per CDC). Healthy postpartum women may be vaccinated with either TIV or LAIV. When vaccine supply is limited, focus on delivering the vaccine should be given to mothers of newborns and contacts or caregivers of children &lt;5 years of age.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F9600966\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Promotes immunity to seasonal influenza virus by inducing specific antibody production. Each year the formulation is standardized according to the U.S. Public Health Service. Preparations from previous seasons must not be used.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F9600968\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Protective antibody titers achieved ~3 weeks after vaccination",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: Protective antibody titers persist approximately &ge;6 months. Elderly: Protective antibody titers may fall &le;4 months after vaccination.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Following nasal administration, vaccine is distributed in the nasal cavity (~90%), stomach (~3%), brain (~2%), and lung (0.4%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Ashkenazi S, Vertruyen A, Arisegui J, et al, &ldquo;Superior Relative Efficacy of Live Attenuated Influenza Vaccine Compared With Inactivated Influenza Vaccine in Young Children With Recurrent Respiratory Tract Infections,&rdquo;",
"      <i>",
"       Pediatr Infect Dis J",
"      </i>",
"      , 2006, 25(10):870-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/54/19303/abstract-text/17006279/pubmed\" id=\"17006279\" target=\"_blank\">",
"        17006279",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bentley DW, &ldquo;Vaccinations,&rdquo;",
"      <i>",
"       Clin Geriatr Med",
"      </i>",
"      , 1992, 8(4):745-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/54/19303/abstract-text/1423132/pubmed\" id=\"1423132\" target=\"_blank\">",
"        1423132",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention, &ldquo;Prevention and Control of Influenza With Vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010,&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2010, 59(RR-8):1-62 . Available at",
"      <a href=\"file://www.cdc.gov/mmwr/PDF/rr/rr5908.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/mmwr/PDF/rr/rr5908.pdf",
"      </a>",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/54/19303/abstract-text/20689501/pubmed\" id=\"20689501\" target=\"_blank\">",
"        20689501",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), &ldquo;Prevention and Control of Influenza With Vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP), United States, 2012-13 Influenza Season,&rdquo;",
"      <i>",
"       MMWR Morb Mortal Wkly Rep",
"      </i>",
"      , 2012, 61(32):613-7. Available at",
"      <a href=\"file://www.cdc.gov/mmwr/preview/mmwrhtml/mm6132a3.htm?s_cid=mm6132a3_w\" target=\"_blank\">",
"       file://www.cdc.gov/mmwr/preview/mmwrhtml/mm6132a3.htm?s_cid=mm6132a3_w",
"      </a>",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/54/19303/abstract-text/21866086/pubmed\" id=\"21866086\" target=\"_blank\">",
"        21866086",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), &ldquo;Recommendations of the Advisory Committee on Immunization Practices (ACIP): General Recommendations on Immunization,&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2011, 60(2):1-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/54/19303/abstract-text/21293327/pubmed\" id=\"21293327\" target=\"_blank\">",
"        21293327",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control, &ldquo;Supplemental Recommendations of the Advisory Committee on Immunization Practices (ACIP): Using Live, Attenuated Influenza Vaccine for Prevention and Control of Influenza,&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2003, 52(RR-13):1-8.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gardner P and Schaffner W, &ldquo;Immunization of Adults,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1993, 328(17):1252-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/54/19303/abstract-text/8464436/pubmed\" id=\"8464436\" target=\"_blank\">",
"        8464436",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Piedra PA, Gaglani MJ, Riggs M, et al, &ldquo;Live Attenuated Influenza Vaccine, Trivalent, is Safe in Healthy Children 18 Months to 4 Years, 5 to 9 Years, and 10 to 18 Years of Age in a Community-Based, Nonrandomized, Open-Label Trial,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2005, 116(3):e397-407.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/54/19303/abstract-text/16140685/pubmed\" id=\"16140685\" target=\"_blank\">",
"        16140685",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Piedra PA, Yan L, Kotloff K, et al. &ldquo;Safety of the Trivalent, Cold-Adapted Influenza Vaccine in Preschool-Aged Children,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2002, 110(4): 662-72.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/54/19303/abstract-text/12359778/pubmed\" id=\"12359778\" target=\"_blank\">",
"        12359778",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Prymula R, Siegrist CA, Chlibek R, et al, &ldquo;Effect of Prophylactic Paracetamol Administration at Time of Vaccination on Febrile Reactions and Antibody Responses in Children: Two Open-Label, Randomised Controlled Trials,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2009, 374(9698):1339-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/54/19303/abstract-text/19837254/pubmed\" id=\"19837254\" target=\"_blank\">",
"        19837254",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Smith SC Jr, Benjamin EJ, Bonow RO, et al, &ldquo;AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2011 Update: A Guideline From the American Heart Association and American College of Cardiology Foundation,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 124(22):2458-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/54/19303/abstract-text/22052934/pubmed\" id=\"22052934\" target=\"_blank\">",
"        22052934",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Steering Committee on Quality Improvement and Management, Subcommittee on Febrile Seizures American Academy of Pediatrics, &ldquo;Febrile seizures: Clinical Practice Guideline for the Long-Term Management of the Child With Simple Febrile Seizures,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2008,  121(6):1281-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/54/19303/abstract-text/18519501/pubmed\" id=\"18519501\" target=\"_blank\">",
"        18519501",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tam JS, Capeding MR, Lum LC, et al, &ldquo;Efficacy and Safety of a Live Attenuated, Cold-Adapted Influenza Vaccine, Trivalent Against Culture-Confirmed Influenza in Young Children in Asia,&rdquo;",
"      <i>",
"       Pediatr Infect Dis J",
"      </i>",
"      , 2007, 26(7):619-28.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/54/19303/abstract-text/17596805/pubmed\" id=\"17596805\" target=\"_blank\">",
"        17596805",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Zaman K, Roy E, Arifeen SE, et al, &ldquo;Effectiveness of Maternal Influenza Immunization in Mothers and Infants,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2008, 9(15):1555-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/54/19303/abstract-text/18799552/pubmed\" id=\"18799552\" target=\"_blank\">",
"        18799552",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9056 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.66.252.144-A6750C7309-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_54_19303=[""].join("\n");
var outline_f18_54_19303=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14961380\">",
"      Special Alerts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9560232\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11239606\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9560235\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9600971\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9560248\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9600972\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15897889\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15897890\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9560249\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9560334\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13845071\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9560338\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9560335\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9560333\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9560239\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9560336\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9600949\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299520\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9600965\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9600944\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9600945\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9600947\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9600948\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9600966\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9600968\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9056\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9056|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?11/43/11953?source=related_link\">",
"      Influenza virus vaccine (live attenuated): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?14/10/14502?source=related_link\">",
"      Influenza virus vaccine (live attenuated): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_54_19304="Weight gain and loss in pregnancy";
var content_f18_54_19304=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Weight gain and loss in pregnancy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/54/19304/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/54/19304/contributors\">",
"     George Macones, MD, MSCE",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/54/19304/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/54/19304/contributors\">",
"     Susan M Ramin, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/54/19304/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/54/19304/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?18/54/19304/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 1, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Maternal prepregnancy weight, body mass index (BMI), pattern of gestational weight gain, and total gestational weight gain are factors determining offspring birth weight, weight for length, and adiposity. Birth weight and adiposity are important because they have a major impact on neonatal morbidity and mortality, and also appear to affect early adult weight and long-term health [",
"    <a class=\"abstract\" href=\"UTD.htm?18/54/19304/abstract/1-5\">",
"     1-5",
"    </a>",
"    ]. As an example, low or high birth weight may affect the child's future risks of developing diabetes, hypertension, and cardiovascular disease. Gestational weight gain also impacts the mother, as excessive gestational weight gain increases her risk of postpartum weight retention and thus increases her risk of becoming obese or developing worsening obesity.",
"   </p>",
"   <p>",
"    Given the importance of gestational weight gain and birth weight, guidelines regarding appropriate levels of weight gain in pregnancy have been promoted worldwide [",
"    <a class=\"abstract\" href=\"UTD.htm?18/54/19304/abstract/6\">",
"     6",
"    </a>",
"    ]. Although the importance of appropriate weight gain is well-established, most women gain too little or too much weight during pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?18/54/19304/abstract/7-9\">",
"     7-9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CHANGE IN WEIGHT RELATED TO PREGNANCY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20253963\">",
"    <span class=\"h2\">",
"     Biologic factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Maternal weight gain during pregnancy can be attributed primarily to increases in maternal body water and fat. On average, weight gain at term is distributed as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Fetus: 7 to 8 pounds (3.2 to 3.6 kg)",
"     </li>",
"     <li>",
"      Fat stores: 6 to 8 pounds (2.7 to 3.6 kg)",
"     </li>",
"     <li>",
"      Increased blood volume: 3 to 4 pounds (1.4 to 1.8 kg)",
"     </li>",
"     <li>",
"      Increased fluid volume: 2 to 3 pounds (0.9 to 1.4 kg)",
"     </li>",
"     <li>",
"      Amniotic fluid: 2 pounds (0.9 kg)",
"     </li>",
"     <li>",
"      Breast enlargement: 1 to 3 pounds (0.45 to 1.4 kg)",
"     </li>",
"     <li>",
"      Uterine hypertrophy: 2 pounds (0.9 kg)",
"     </li>",
"     <li>",
"      Placenta: 1.5 pounds (0.7 kg)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the absence of pathological edema (eg, preeclampsia), excessive gestational weight gain is primarily related to an excessive increase in maternal adiposity. There are several biologic and genetic factors that affect fat metabolism both during and after pregnancy. For example, increased progesterone levels during pregnancy are responsible for fat accumulation during the first and second trimesters, and for fat mobilization during the third trimester. Increased leptin levels during pregnancy correlate positively with body fat content and body mass index (BMI) and appear to play a direct role in gestational weight gain and postpartum weight retention [",
"    <a class=\"abstract\" href=\"UTD.htm?18/54/19304/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/50/13094?source=see_link\">",
"     \"Physiology of leptin\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20253941\">",
"    <span class=\"h2\">",
"     Other factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women experience modest increases in body weight and fat distribution after a first pregnancy; these changes are persistent and vary according to race and ethnic background [",
"    <a class=\"abstract\" href=\"UTD.htm?18/54/19304/abstract/12\">",
"     12",
"    </a>",
"    ]. In longitudinal studies, African American women had three-fold higher median gestational weight gain than Caucasian women and they were twice as likely to have postpartum weight retention &gt;4 kg at one-year [",
"    <a class=\"abstract\" href=\"UTD.htm?18/54/19304/abstract/13-16\">",
"     13-16",
"    </a>",
"    ]. These relationships remained even when prepregnancy weight was normal. In contrast, Hispanic women were more likely to have inadequate gestational weight gain (based on Institute of Medicine [IOM] guidelines) when compared to their non-Hispanic counterparts [",
"    <a class=\"abstract\" href=\"UTD.htm?18/54/19304/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to race and ethnicity, many other variables contribute to gestational weight gain and postpartum weight retention, including marital status, age, income, education, occupation, working outside of the home, physical activity, and smoking.",
"   </p>",
"   <p>",
"    Postpartum weight retention is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/30/39402?source=see_link&amp;anchor=H46#H46\">",
"     \"Overview of postpartum care\", section on 'Postpartum weight retention'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     RECOMMENDATIONS FOR WEIGHT GAIN DURING PREGNANCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the 1930s, all pregnant women in the United States, irrespective of pregravid weight status, were advised to gain only 15 pounds (6.8 kg). Severe dietary restriction was a common obstetrical practice based on the belief that excessive gestational weight gain led to the development of preeclampsia and other obstetrical problems [",
"    <a class=\"abstract\" href=\"UTD.htm?18/54/19304/abstract/18\">",
"     18",
"    </a>",
"    ]. Weight gain recommendations became more liberal when studies demonstrated that dietary restriction was associated with an increased risk of low birth weight and neurologically impaired infants [",
"    <a class=\"abstract\" href=\"UTD.htm?18/54/19304/abstract/19-22\">",
"     19-22",
"    </a>",
"    ]. Therefore, in the late 1970s and 1980s, recommendations for gestational weight gain increased to 20 to 25 pounds (9 to 11 kg) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/54/19304/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In 1987, the Committee on Nutritional Status During Pregnancy and Lactation of the Institute of Medicine (IOM) made a detailed analysis of all published data pertaining to prepregnancy weight, weight gain during pregnancy, and pregnancy outcome and, based on this analysis, formulated recommendations for healthy gestational weight gain in 1990 [",
"    <a class=\"abstract\" href=\"UTD.htm?18/54/19304/abstract/24\">",
"     24",
"    </a>",
"    ]. These recommendations were an attempt to increase the likelihood of a favorable pregnancy outcome, which was defined as delivery of a term liveborn infant with a birth weight between 3000 and 4000 grams. It was assumed that increasing maternal weight gain among underweight women would lower the rate of low birth weight and its associated perinatal morbidity and mortality, without adversely affecting other obstetrical outcomes. Little was known about the relationship between weight gain, birth weight, and pregnancy outcome in the obese women. The IOM also concluded that prepregnancy body mass index (BMI) (",
"    <a class=\"graphic graphic_table graphicRef80542 \" href=\"UTD.htm?2/54/2927\">",
"     table 1",
"    </a>",
"    ) was an important predictor of birth weight, independent of maternal weight gain, and should be used to guide recommendations for gestational weight gain. Thus, determining BMI became an integral part of the physical examination of pregnant women.",
"   </p>",
"   <p>",
"    In the absence of definitive data, 1990 IOM guidelines recommended what the authors considered an optimum weight gain for women with a normal BMI (25 to 35 pounds [11 to 16 kg]), with lower weight gain for women beginning pregnancy at higher BMIs (with no upper limit) and higher weight gain for women beginning pregnancy at lower BMIs. The studies on which the 1990 recommendations were based were generally not of high quality; thus, more research was needed to validate or modify these guidelines.",
"   </p>",
"   <p>",
"    In 2009, the IOM modified the 1990 guidelines based on findings from research performed over almost two decades following their initial recommendations. The 2009 guideline included recommendations for gestational weight gain in twin pregnancy and changes to the recommendations for obese women (",
"    <a class=\"graphic graphic_table graphicRef75820 \" href=\"UTD.htm?18/50/19244\">",
"     table 2",
"    </a>",
"    ); the IOM also recommended that all women strive to be within the normal BMI range when they conceive [",
"    <a class=\"abstract\" href=\"UTD.htm?18/54/19304/abstract/25\">",
"     25",
"    </a>",
"    ]. The World Health Organization (WHO) criteria for defining weight categories were adopted in the revision, as well. There were insufficient data on which to base recommendations for weight gain in triplet and higher order multiple gestations or for the different classes of obesity (class I BMI 30 to 34.9, class II BMI &lt;35 to 39.9, class III BMI &ge;40).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1230637565\">",
"    <span class=\"h2\">",
"     2009 IOM weight gain recommendations",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Singleton pregnancy",
"      </strong>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      BMI &lt;18.5",
"      <span class=\"nowrap\">",
"       kg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      (underweight) &mdash; weight gain 28 to 40 lbs (12.5 to 18.0 kg)",
"     </li>",
"     <li>",
"      BMI 18.5 to 24.9",
"      <span class=\"nowrap\">",
"       kg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      (normal weight) &mdash; weight gain 25 to 35 lbs (11.5 to 16.0 kg)",
"     </li>",
"     <li>",
"      BMI 25.0 to 29.9",
"      <span class=\"nowrap\">",
"       kg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      (overweight) &mdash; weight gain 15 to 25 lbs (7.0 to 11.5 kg)",
"     </li>",
"     <li>",
"      BMI &ge;30.0",
"      <span class=\"nowrap\">",
"       kg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      (obese) &mdash; weight gain 11 to 20 lbs (5 to 9.0 kg)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Twin pregnancy",
"      </strong>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      BMI &lt;18.5",
"      <span class=\"nowrap\">",
"       kg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      (underweight) &mdash; no recommendation due to insufficient data",
"     </li>",
"     <li>",
"      BMI 18.5 to 24.9",
"      <span class=\"nowrap\">",
"       kg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      (normal weight) &mdash; weight gain 37 to 54 lbs (16.8 to 24.5 kg)",
"     </li>",
"     <li>",
"      BMI 25.0 to 29.9",
"      <span class=\"nowrap\">",
"       kg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      (overweight) &mdash; weight gain 31 to 50 lbs (14.1 to 22.7 kg)",
"     </li>",
"     <li>",
"      BMI &ge;30.0",
"      <span class=\"nowrap\">",
"       kg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      (obese) &mdash; weight gain 25 to 42 lbs (11.4 to 19.1 kg)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These recommendations are for the general obstetrical population in the United States, and are independent of age, parity, smoking history, race, and ethnic background. The relationship between weight gain and pregnancy outcome has not been evaluated extensively in subpopulations of pregnant women, and further study is needed. For example, teenagers may benefit from higher weight gain [",
"    <a class=\"abstract\" href=\"UTD.htm?18/54/19304/abstract/26\">",
"     26",
"    </a>",
"    ] and women with severe or class II or III obesity may benefit from lower weight gain targets than women with milder or class I obesity. &nbsp;",
"   </p>",
"   <p>",
"    For underweight and normal weight women, the guidelines translate to about one pound (0.4 kg) weight gain per week in the second and third trimesters; for overweight and obese women, the guidelines translate to about one-half pound (0.2 kg) weight gain per week in the second and third trimesters (",
"    <a class=\"graphic graphic_table graphicRef75820 \" href=\"UTD.htm?18/50/19244\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    If weight gain is less than one-half pound (0.2 kg) per week or more than one and a half pounds (0.7 kg) per week, clinicians are advised to evaluate the woman's eating habits and other potential etiologies of deficient or excessive weight gain (eg, smoking is strongly associated with inadequate weight gain, weight gain can be due to edema or fat accretion) and to evaluate whether fetal growth is adequate or impacted by insufficient or excessive maternal weight gain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     OUTCOME OF 1990 IOM RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The RTI International&ndash;University of North Carolina at Chapel Hill Evidence-based Practice Center (EPC) conducted a systematic review of 150 studies published from 1990 (year Institute of Medicine [IOM] recommendations released) to 2007 that examined the influence of gestational weight gain on various pregnancy outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?18/54/19304/abstract/27\">",
"     27",
"    </a>",
"    ]. The studies were almost all observational with no standardization of definitions, methodology, or statistical analysis of outcomes, and limited long-term follow-up.",
"   </p>",
"   <p>",
"    The major findings from this systematic review were:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Moderate evidence of an increased risk of cesarean delivery with increasing gestational weight gain. The association between risk of cesarean delivery and gestational weight gain was least strong in obese women, probably because these women were already at high risk of requiring cesarean birth.",
"     </li>",
"     <li>",
"      The majority of studies found a consistent effect of low gestational weight gain on preterm birth and a less consistent effect of high gestational weight gain on preterm birth. The association for low gestational weight gain held whether total weight gain or rate of weight gain was considered. Low rates of weight gain were &le;0.37 kg per week and high rates of weight gain were &gt;0.52 kg per week throughout gestation.",
"     </li>",
"     <li>",
"      Strong evidence of an association between gestational weight gain and birth weight. Low gestational weight gain was associated with lower birth weights across all pregravid weight status groups, while high gestational weight gain resulted in higher birth weight, primarily in underweight and normal weight women. For every 1 kg increase in gestational weight gain, birth weight increased by 16.7 to 22.6 g.",
"     </li>",
"     <li>",
"      Strong evidence that high gestational weight gain is associated with greater risks of macrosomia (&gt;4500 g or &gt;4000 g). Strong evidence of an association between high gestational weight gain and birth of a large for gestational age infant.",
"     </li>",
"     <li>",
"      Strong evidence that low gestational weight gain is associated with greater risks of having a small for gestational age infant.",
"     </li>",
"     <li>",
"      Moderate evidence of an association between high gestational weight gain, and weight retention later in life; however, the magnitude of weight retained was small. At one year postpartum, a higher percentage of weight gained within the first 20 weeks of gestation was retained at 6 weeks postpartum compared to weight gains later in pregnancy. In addition, overweight and obese women retained more weight compared to normal weight women. Obese women appeared to be at risk for increases in fat mass and central adiposity in the postpartum period.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Data for several other outcomes were weak or insufficient; therefore, no conclusions could be made. The large body of evidence that women whose gestational weight gain is within IOM guidelines are less likely to deliver infants at the extremes of birth weight for gestational age is an important finding since very low and very high birth weights are clearly associated with increased neonatal morbidity and mortality. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/23/9593?source=see_link\">",
"     \"Small for gestational age infant\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/21/20823?source=see_link\">",
"     \"Large for gestational age newborn\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The argument against gestational weight gain above the IOM's guidelines has largely been based on studies showing that it leads to postpartum weight retention and future adult obesity, which is reaching epidemic proportions in developed countries [",
"    <a class=\"abstract\" href=\"UTD.htm?18/54/19304/abstract/28-30\">",
"     28-30",
"    </a>",
"    ]. The 2009 IOM report stated that an analysis restricted to data collected at 24 weeks postpartum or later found that more than 60 percent of women in all",
"    <span class=\"nowrap\">",
"     racial/ethnic",
"    </span>",
"    groups who gained above the range recommended by IOM 1990 retained &gt;10 pounds postpartum and more than 40 percent of women who gained excessively retained &gt;20 pounds [",
"    <a class=\"abstract\" href=\"UTD.htm?18/54/19304/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Gestational weight gain above the IOM's guidelines has other adverse maternal and neonatal effects. Although gestational weight gain above IOM recommendations is associated with fewer newborns weighing less than 3000 grams among women with low prepregnancy BMI, this is not the case for women with prepregnancy BMI in the normal, overweight, or obese women. For these women, gestational weight gain above IOM recommendations does not decrease the rate of infants weighing less than 3000 grams, but does appear to lead to higher mean birth weight, a higher rate of large for gestational age infants, and an increase in suboptimal neonatal outcomes. In these women, any birth weight benefits associated with a higher mean birth weight are offset by the increased risks of delivering a large for gestational age infant, neonatal morbidity associated with higher mean birth weight, and maternal morbidity stemming from higher body weight [",
"    <a class=\"abstract\" href=\"UTD.htm?18/54/19304/abstract/31,32\">",
"     31,32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21938069\">",
"    <span class=\"h1\">",
"     EFFECT OF WEIGHT LOSS IN OBESE WOMEN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Further investigation is needed to assess the safety and effectiveness of weight loss in obese women during pregnancy; no randomized trials have been performed [",
"    <a class=\"abstract\" href=\"UTD.htm?18/54/19304/abstract/33\">",
"     33",
"    </a>",
"    ]. Available data suggest weight loss in these women decreases some pregnancy complications associated with obesity, but also reduces birth weight [",
"    <a class=\"abstract\" href=\"UTD.htm?18/54/19304/abstract/34-40\">",
"     34-40",
"    </a>",
"    ]. However, a small (&lt;5 kg) weight loss in class II and III obese women (body mass index [BMI] 35.0 to 39.9 and BMI &ge;40, respectively) appears to have more benefits than risks, and may not increase the risk of having a small for gestational age infant. The following studies illustrate the range of findings in the literature:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A logistic regression analysis with data from 122,327 obese mothers concluded that for class II and III obese women, gestational weight loss &lt;5 kg did not increase the odds of small for gestational age infants, and decreased the odds of macrosomia [",
"      <a class=\"abstract\" href=\"UTD.htm?18/54/19304/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A population-based retrospective cohort study of 120,251 pregnant, obese women delivering full-term, liveborn, singleton infants assessed the risk of four pregnancy outcomes (preeclampsia, cesarean delivery, small for gestational age births, and large for gestational age births) by obesity class and total gestational weight gain [",
"      <a class=\"abstract\" href=\"UTD.htm?18/54/19304/abstract/36\">",
"       36",
"      </a>",
"      ]. The minimal risk for all four outcomes corresponded to the gestational weight change where the risk of large and small for gestational age births intersected, which was a weight loss &lt;4 kg for class III obese women.",
"     </li>",
"     <li>",
"      A population-based retrospective cohort study of 46,595 women of obesity class I, II, and III observed that weight loss decreased their risk of cesarean delivery, preeclampsia, and large for gestational infants, sometimes significantly, but increased their risk of having a small for gestational age infant compared to obese women who achieved Institute of Medicine (IOM) weight gain recommendations [",
"      <a class=\"abstract\" href=\"UTD.htm?18/54/19304/abstract/39\">",
"       39",
"      </a>",
"      ]. However, their rate of small for gestational age infants was similar to that in the general population.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Weight loss may be accompanied by ketonuria. Ketonuria may be due to a fasting state, poor dietary intake, nausea and vomiting, or uncontrolled diabetes. Nutritional",
"    <span class=\"nowrap\">",
"     assessment/intake",
"    </span>",
"    can be helpful in these cases. The effects of ketonuria during pregnancy or labor on the woman and her baby are unclear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     COUNSELING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Health care providers should determine a woman&rsquo;s body mass index (BMI) during preconceptional counseling and at the first prenatal visit [",
"    <a class=\"abstract\" href=\"UTD.htm?18/54/19304/abstract/41\">",
"     41",
"    </a>",
"    ]. This information should be used to guide recommendations regarding diet, exercise, and weight",
"    <span class=\"nowrap\">",
"     gain/loss",
"    </span>",
"    before, during, and after pregnancy. In a survey of Canadian women, only a minority reported being counselled correctly about how much weight&nbsp;to&nbsp;gain&nbsp;during pregnancy or the risks of inappropriate weight gain [",
"    <a class=\"abstract\" href=\"UTD.htm?18/54/19304/abstract/42\">",
"     42",
"    </a>",
"    ].&nbsp;Similarly, a 2007-2009 survey of obstetrical providers in Massachusetts noted 37 percent did not correctly report the minimum BMI for diagnosing obesity, and most advised gestational weight gains that were discordant with 1990 Institute of Medicine (IOM) guidelines, especially for obese women [",
"    <a class=\"abstract\" href=\"UTD.htm?18/54/19304/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18139899\">",
"    <span class=\"h2\">",
"     Women of normal weight",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women who have a BMI in the normal range should be educated about nutrition, physical activity, exercise, and appropriate weight gain during pregnancy. It may be useful to explain that caloric intake doesn&rsquo;t need to increase in early pregnancy, as weekly weight gain in the first trimester should be minimal. Later in pregnancy, caloric intake needs to increase by only 200 to 300 calories per day to achieve one pound (0.5 kg) weight gain per week. It may also be useful to dispel myths such as &ldquo;eating for two.&rdquo; (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/44/28362?source=see_link\">",
"     \"Nutrition in pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/30/7657?source=see_link\">",
"     \"Recommendations for exercise during pregnancy and the postpartum period\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although weighing all prenatal patients at every prenatal visit is routine in the United States, National Institute for Health and Clinical Excellence (NICE) guidelines suggest that women who begin pregnancy with a normal BMI and do not have comorbidities (eg, diabetes) do not need to be weighed repeatedly during pregnancy as a matter of routine, but should be weighed again after the first prenatal visit if clinical management will be influenced or if nutrition is a concern [",
"    <a class=\"abstract\" href=\"UTD.htm?18/54/19304/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20254135\">",
"    <span class=\"h2\">",
"     Overweight and obese women",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women who are overweight or obese",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    gain excessive weight in pregnancy are a frequent occurrence in the United States. In 2003, 40.5 percent of women who delivered were overweight or obese prepregnancy by IOM definitions [",
"    <a class=\"abstract\" href=\"UTD.htm?18/54/19304/abstract/28\">",
"     28",
"    </a>",
"    ]. From 1990 to 2010, the percentage of pregnant women who gained &gt;18 kg (40 pounds) by term increased from 16 percent to 21 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?18/54/19304/abstract/45\">",
"     45",
"    </a>",
"    ]. In 2004 to 2005, 40 percent of normal weight women and 60 percent of overweight women gained excessive weight during pregnancy (defined as &gt;16 kg [35 pounds] for normal weight women and &gt;11 kg [25 pounds] for overweight women) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/54/19304/abstract/46\">",
"     46",
"    </a>",
"    ]. Data from the 2009-2010 National Health and Nutrition Examination Survey (NHANES) showed that 31.9 percent of women of reproductive age (20 to 39 years old) were obese (BMI &ge;30",
"    <span class=\"nowrap\">",
"     kg/m",
"     <sup>",
"      2",
"     </sup>",
"     );",
"    </span>",
"    the prevalence was highest in non-Hispanic blacks (56.2 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/54/19304/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Prepregnancy counseling should include information on the risks of obesity for the mother, pregnancy, and child (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/11/29882?source=see_link\">",
"     \"The impact of obesity on fertility and pregnancy\"",
"    </a>",
"    ) and encouragement for weight reduction, which may include information about diet, exercise, and weight loss programs, and referral to a weight-reduction specialist for discussion of options such as behavior modification, pharmacotherapy, or bariatric surgery, if appropriate (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/45/13016?source=see_link\">",
"     \"Overview of therapy for obesity in adults\"",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Pregnancy is the only time in an overweight or obese woman's life when she is encouraged to gain weight. Given the high prevalence of",
"    <span class=\"nowrap\">",
"     overweight/obese",
"    </span>",
"    pregnant women and excessive weight gain in pregnancy, and the potential adverse effects of both high maternal BMI and high gestational weight gain, avoidance of excessive weight gain, rather than prevention of inadequate gain, should be the focus of weight gain counseling during prenatal care. This discussion should occur early in the woman&rsquo;s first pregnancy, as excessive weight gain in a first pregnancy is predictive of excessive weight gain in subsequent pregnancies [",
"    <a class=\"abstract\" href=\"UTD.htm?18/54/19304/abstract/48\">",
"     48",
"    </a>",
"    ]. As women are particularly concerned about their health and the health of their babies during pregnancy, and in frequent contact with their healthcare providers, pregnancy is an ideal time for promotion of weight control and adoption of a healthy lifestyle [",
"    <a class=\"abstract\" href=\"UTD.htm?18/54/19304/abstract/49\">",
"     49",
"    </a>",
"    ]. Overweight and obese pregnant women could benefit from a nutritional consultation. Electronic medical record-based tools that alert the clinician to women with excessive weight gain may improve identification and counseling of these women at each prenatal visit [",
"    <a class=\"abstract\" href=\"UTD.htm?18/54/19304/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As in nonpregnant individuals, a healthy diet and exercise (if there are no contraindications) help to prevent excessive weight gain [",
"    <a class=\"abstract\" href=\"UTD.htm?18/54/19304/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/45/13016?source=see_link\">",
"     \"Overview of therapy for obesity in adults\"",
"    </a>",
"    .) Several systematic reviews and meta-analyses have examined the effect of antenatal behavioral intervention (eg, counseling about diet, physical activity, and optimum weight gain; goal setting) for prevention of excessive weight gain during pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?18/54/19304/abstract/53-58\">",
"     53-58",
"    </a>",
"    ]. Although some of these analyses found these interventions significantly decreased gestational weight gain compared with usual care, there was no clear reduction in maternal complications or adverse neonatal outcomes. Published intervention trials have generally been of small size and insufficient quality to allow evidence-based recommendations to be developed for clinical practice in antenatal care [",
"    <a class=\"abstract\" href=\"UTD.htm?18/54/19304/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We do not advise",
"    <span class=\"nowrap\">",
"     overweight/obese",
"    </span>",
"    women with gestational weight gain below that recommended by the IOM to increase weight gain if the fetus is growing appropriately. The optimum amount of weight gain for",
"    <span class=\"nowrap\">",
"     overweight/obese",
"    </span>",
"    women is controversial. Maternal obesity is protective against low birth weight and the tendency towards higher birth weight percentiles persists, even in the presence of factors which might be expected to lower birth weight (eg, low maternal weight gain, chronic hypertension) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/54/19304/abstract/60\">",
"     60",
"    </a>",
"    ]. Our approach is supported by several studies in which overweight women who gained only 6 to 14 pounds (2.7 to 6.4 kg) had similar neonatal outcomes as overweight women whose weight gain was higher and within IOM recommendations of 15 to 25 pounds (7.0 to 11.5 kg) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/54/19304/abstract/34,61-65\">",
"     34,61-65",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20254142\">",
"    <span class=\"h2\">",
"     Underweight women",
"    </span>",
"    &nbsp;&mdash;&nbsp;Underweight women should be encouraged to meet IOM recommendations for gestational weight gain to lower their risk of spontaneous preterm birth and having a small for gestational age infant [",
"    <a class=\"abstract\" href=\"UTD.htm?18/54/19304/abstract/27,66\">",
"     27,66",
"    </a>",
"    ]. Referral to a nutritionist might be helpful. The presence of an eating disorder should be considered. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/38/7781?source=see_link\">",
"     \"Eating disorders in pregnant women\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?36/29/37331?source=see_link\">",
"       \"Patient information: Prenatal care (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Maternal body mass index (BMI) and gestational weight gain are important predictors of neonatal weight and short- and long-term well-being. High prepregnancy BMI, maternal adiposity, and excessive gestational weight gain are risk factors for delivering a large for gestational age infant, adverse pregnancy outcome, childhood obesity, and metabolic changes associated with poor health. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Physiological changes related to pregnancy result in a weight gain of about 25 pounds (11 kg). In the absence of pathological edema, excessive gestational weight gain is primarily due to an excessive increase in fat stores. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Change in weight related to pregnancy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is strong evidence of a positive association between gestational weight gain and birth weight. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Outcome of 1990 IOM recommendations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The Institute of Medicine (IOM) recommendations for weight gain during pregnancy are based on maternal prepregnancy BMI and intended primarily to lower the risk of low birth weight delivery, which is primarily associated with low gestational weight gain in low BMI women. The initial focus of the recommendations was not prevention of excessive weight gain, which is increasingly a problem in contemporary society. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Recommendations for weight gain during pregnancy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Prepregnancy and postpartum counseling of",
"      <span class=\"nowrap\">",
"       overweight/obese",
"      </span>",
"      women should include information on the risks of obesity for the mother, pregnancy, and child and encouragement for weight reduction, which may include information about diet, exercise, and weight loss programs, and referral to a weight-reduction specialist for discussion of options such as behavior modification, pharmacotherapy, or bariatric surgery, if appropriate. (See",
"      <a class=\"local\" href=\"#H20254135\">",
"       'Overweight and obese women'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We generally agree with IOM recommendations for gestational weight gain. For",
"      <span class=\"nowrap\">",
"       overweight/obese",
"      </span>",
"      women with gestational weight gain below that recommended by the IOM and appropriate fetal growth, we do not suggest increased weight gain (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H20254135\">",
"       'Overweight and obese women'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women with BMI &gt;35",
"      <span class=\"nowrap\">",
"       kg/m",
"       <sup>",
"        2",
"       </sup>",
"       ,",
"      </span>",
"      a small weight loss or maintenance of weight may be advantageous overall, although",
"      <span class=\"nowrap\">",
"       risk/benefit",
"      </span>",
"      analyses are ongoing. (See",
"      <a class=\"local\" href=\"#H21938069\">",
"       'Effect of weight loss in obese women'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19304/abstract/1\">",
"      Mamun AA, O'Callaghan M, Callaway L, et al. Associations of gestational weight gain with offspring body mass index and blood pressure at 21 years of age: evidence from a birth cohort study. Circulation 2009; 119:1720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19304/abstract/2\">",
"      Fraser A, Tilling K, Macdonald-Wallis C, et al. Association of maternal weight gain in pregnancy with offspring obesity and metabolic and vascular traits in childhood. Circulation 2010; 121:2557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19304/abstract/3\">",
"      Hochner H, Friedlander Y, Calderon-Margalit R, et al. Associations of maternal prepregnancy body mass index and gestational weight gain with adult offspring cardiometabolic risk factors: the Jerusalem Perinatal Family Follow-up Study. Circulation 2012; 125:1381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19304/abstract/4\">",
"      Ehrenthal DB, Maiden K, Rao A, et al. Independent relation of maternal prenatal factors to early childhood obesity in the offspring. Obstet Gynecol 2013; 121:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19304/abstract/5\">",
"      Poston L. Maternal obesity, gestational weight gain and diet as determinants of offspring long term health. Best Pract Res Clin Endocrinol Metab 2012; 26:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19304/abstract/6\">",
"      Alavi N, Haley S, Chow K, McDonald SD. Comparison of national gestational weight gain guidelines and energy intake recommendations. Obes Rev 2013; 14:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19304/abstract/7\">",
"      Chung JG, Taylor RS, Thompson JM, et al. Gestational weight gain and adverse pregnancy outcomes in a nulliparous cohort. Eur J Obstet Gynecol Reprod Biol 2013; 167:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19304/abstract/8\">",
"      Daemers DO, Wijnen HA, van Limbeek EB, et al. Patterns of gestational weight gain in healthy, low-risk pregnant women without co-morbidities. Midwifery 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19304/abstract/9\">",
"      Ferraro ZM, Barrowman N, Prud'homme D, et al. Excessive gestational weight gain predicts large for gestational age neonates independent of maternal body mass index. J Matern Fetal Neonatal Med 2012; 25:538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19304/abstract/10\">",
"      Butte NF, Hopkinson JM, Nicolson MA. Leptin in human reproduction: serum leptin levels in pregnant and lactating women. J Clin Endocrinol Metab 1997; 82:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19304/abstract/11\">",
"      Stein TP, Scholl TO, Schluter MD, Schroeder CM. Plasma leptin influences gestational weight gain and postpartum weight retention. Am J Clin Nutr 1998; 68:1236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19304/abstract/12\">",
"      Smith DE, Lewis CE, Caveny JL, et al. Longitudinal changes in adiposity associated with pregnancy. The CARDIA Study. Coronary Artery Risk Development in Young Adults Study. JAMA 1994; 271:1747.",
"     </a>",
"    </li>",
"    <li>",
"     Gunderson, EP, Adams, B. Weight Gain and Body Weight changes after pregnancy. Epidemiologic Reviews 1998.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19304/abstract/14\">",
"      Parker JD, Abrams B. Differences in postpartum weight retention between black and white mothers. Obstet Gynecol 1993; 81:768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19304/abstract/15\">",
"      Greene GW, Smiciklas-Wright H, Scholl TO, Karp RJ. Postpartum weight change: how much of the weight gained in pregnancy will be lost after delivery? Obstet Gynecol 1988; 71:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19304/abstract/16\">",
"      Keppel KG, Taffel SM. Pregnancy-related weight gain and retention: implications of the 1990 Institute of Medicine guidelines. Am J Public Health 1993; 83:1100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19304/abstract/17\">",
"      Wells CS, Schwalberg R, Noonan G, Gabor V. Factors influencing inadequate and excessive weight gain in pregnancy: Colorado, 2000-2002. Matern Child Health J 2006; 10:55.",
"     </a>",
"    </li>",
"    <li>",
"     Eastman NJ. Williams Obstetrics, 10th ed, Appleton-Century-Crofts, New York 1950.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19304/abstract/19\">",
"      Singer JE, Westphal M, Niswander K. Relationship of weight gain during pregnancy to birth weight and infant growth and development in the first year of life. Obstet Gynecol 1968; 31:417.",
"     </a>",
"    </li>",
"    <li>",
"     Committee on Maternal Nutrition/Food and Nutrition Board, National Research Council: Maternal Nutrition and the Course of Pregnancy, Washington DC 1970.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19304/abstract/21\">",
"      Taffel SM. Maternal weight gain and the outcome of pregnancy. Vital Health Stat 21 1986; :1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19304/abstract/22\">",
"      Stotland NE, Caughey AB, Lahiff M, Abrams B. Weight gain and spontaneous preterm birth: the role of race or ethnicity and previous preterm birth. Obstet Gynecol 2006; 108:1448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19304/abstract/23\">",
"      Taffel SM, Keppel KG. Advice about weight gain during pregnancy and actual weight gain. Am J Public Health 1986; 76:1396.",
"     </a>",
"    </li>",
"    <li>",
"     Institute of Medicine, Food and Nutrition Board, Committee on Nutritional Status During Pregnancy, part I: Nutritional Status and Weight Gain. National Academy Press, Washington DC 2000.",
"    </li>",
"    <li>",
"     www.iom.edu/CMS/3788/48191/68004/68230.aspx. (Accessed May 29, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19304/abstract/26\">",
"      Harper LM, Chang JJ, Macones GA. Adolescent pregnancy and gestational weight gain: do the Institute of Medicine recommendations apply? Am J Obstet Gynecol 2011; 205:140.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19304/abstract/27\">",
"      Viswanathan M, Siega-Riz AM, Moos MK, et al. Outcomes of maternal weight gain. Evid Rep Technol Assess (Full Rep) 2008; :1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19304/abstract/28\">",
"      Yeh J, Shelton JA. Increasing prepregnancy body mass index: analysis of trends and contributing variables. Am J Obstet Gynecol 2005; 193:1994.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19304/abstract/29\">",
"      Rooney BL, Schauberger CW, Mathiason MA. Impact of perinatal weight change on long-term obesity and obesity-related illnesses. Obstet Gynecol 2005; 106:1349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19304/abstract/30\">",
"      Nehring I, Schmoll S, Beyerlein A, et al. Gestational weight gain and long-term postpartum weight retention: a meta-analysis. Am J Clin Nutr 2011; 94:1225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19304/abstract/31\">",
"      Stotland NE, Cheng YW, Hopkins LM, Caughey AB. Gestational weight gain and adverse neonatal outcome among term infants. Obstet Gynecol 2006; 108:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19304/abstract/32\">",
"      Hedderson MM, Weiss NS, Sacks DA, et al. Pregnancy weight gain and risk of neonatal complications: macrosomia, hypoglycemia, and hyperbilirubinemia. Obstet Gynecol 2006; 108:1153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19304/abstract/33\">",
"      Furber CM, McGowan L, Bower P, et al. Antenatal interventions for reducing weight in obese women for improving pregnancy outcome. Cochrane Database Syst Rev 2013; 1:CD009334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19304/abstract/34\">",
"      Oken E, Kleinman KP, Belfort MB, et al. Associations of gestational weight gain with short- and longer-term maternal and child health outcomes. Am J Epidemiol 2009; 170:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19304/abstract/35\">",
"      Hinkle SN, Sharma AJ, Dietz PM. Gestational weight gain in obese mothers and associations with fetal growth. Am J Clin Nutr 2010; 92:644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19304/abstract/36\">",
"      Kiel DW, Dodson EA, Artal R, et al. Gestational weight gain and pregnancy outcomes in obese women: how much is enough? Obstet Gynecol 2007; 110:752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19304/abstract/37\">",
"      Beyerlein A, Schiessl B, Lack N, von Kries R. Associations of gestational weight loss with birth-related outcome: a retrospective cohort study. BJOG 2011; 118:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19304/abstract/38\">",
"      Vesco KK, Sharma AJ, Dietz PM, et al. Newborn size among obese women with weight gain outside the 2009 Institute of Medicine recommendation. Obstet Gynecol 2011; 117:812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19304/abstract/39\">",
"      Blomberg M. Maternal and neonatal outcomes among obese women with weight gain below the new Institute of Medicine recommendations. Obstet Gynecol 2011; 117:1065.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19304/abstract/40\">",
"      Reynolds S, Moran J, Addy M, et al. Taurolin as an oral rinse. I. Antimicrobial effects in vitro and in vivo. Clin Prev Dent 1991; 13:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19304/abstract/41\">",
"      ACOG Committee opinion no. 548: weight gain during pregnancy. Obstet Gynecol 2013; 121:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19304/abstract/42\">",
"      McDonald SD, Pullenayegum E, Bracken K, et al. Comparison of midwifery, family medicine, and obstetric patients' understanding of weight gain during pregnancy: a minority of women report correct counselling. J Obstet Gynaecol Can 2012; 34:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19304/abstract/43\">",
"      Herring SJ, Platek DN, Elliott P, et al. Addressing obesity in pregnancy: what do obstetric providers recommend? J Womens Health (Larchmt) 2010; 19:65.",
"     </a>",
"    </li>",
"    <li>",
"     NICE public health guidance 27: Weight management before, during and after pregnancy. July 2010 file://guidance.nice.org.uk/PH27/Guidance/pdf/English (Accessed on June 15, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19304/abstract/45\">",
"      Births: Final data for 2010. Natl Vital Stat Rep 2012; 61:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19304/abstract/46\">",
"      Chu SY, Callaghan WM, Bish CL, D'Angelo D. Gestational weight gain by body mass index among US women delivering live births, 2004-2005: fueling future obesity. Am J Obstet Gynecol 2009; 200:271.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19304/abstract/47\">",
"      Flegal KM, Carroll MD, Kit BK, Ogden CL. Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010. JAMA 2012; 307:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19304/abstract/48\">",
"      Chin JR, Krause KM, Ostbye T, et al. Gestational weight gain in consecutive pregnancies. Am J Obstet Gynecol 2010; 203:279.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19304/abstract/49\">",
"      Phelan S. Pregnancy: a \"teachable moment\" for weight control and obesity prevention. Am J Obstet Gynecol 2010; 202:135.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19304/abstract/50\">",
"      Oken E, Switkowski K, Price S, et al. A Qualitative Study of Gestational Weight Gain Counseling and Tracking. Matern Child Health J 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19304/abstract/51\">",
"      Stuebe AM, Oken E, Gillman MW. Associations of diet and physical activity during pregnancy with risk for excessive gestational weight gain. Am J Obstet Gynecol 2009; 201:58.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19304/abstract/52\">",
"      Streuling I, Beyerlein A, Rosenfeld E, et al. Physical activity and gestational weight gain: a meta-analysis of intervention trials. BJOG 2011; 118:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19304/abstract/53\">",
"      Quinlivan JA, Julania S, Lam L. Antenatal dietary interventions in obese pregnant women to restrict gestational weight gain to Institute of Medicine recommendations: a meta-analysis. Obstet Gynecol 2011; 118:1395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19304/abstract/54\">",
"      Streuling I, Beyerlein A, von Kries R. Can gestational weight gain be modified by increasing physical activity and diet counseling? A meta-analysis of interventional trials. Am J Clin Nutr 2010; 92:678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19304/abstract/55\">",
"      Dodd JM, Grivell RM, Crowther CA, Robinson JS. Antenatal interventions for overweight or obese pregnant women: a systematic review of randomised trials. BJOG 2010; 117:1316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19304/abstract/56\">",
"      Muktabhant B, Lumbiganon P, Ngamjarus C, Dowswell T. Interventions for preventing excessive weight gain during pregnancy. Cochrane Database Syst Rev 2012; 4:CD007145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19304/abstract/57\">",
"      Thangaratinam S, Rogozinska E, Jolly K, et al. Effects of interventions in pregnancy on maternal weight and obstetric outcomes: meta-analysis of randomised evidence. BMJ 2012; 344:e2088.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19304/abstract/58\">",
"      Brown MJ, Sinclair M, Liddle D, et al. A systematic review investigating healthy lifestyle interventions incorporating goal setting strategies for preventing excess gestational weight gain. PLoS One 2012; 7:e39503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19304/abstract/59\">",
"      Ronnberg AK, Nilsson K. Interventions during pregnancy to reduce excessive gestational weight gain: a systematic review assessing current clinical evidence using the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) system. BJOG 2010; 117:1327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19304/abstract/60\">",
"      Gross T, Sokol RJ, King KC. Obesity in pregnancy: risks and outcome. Obstet Gynecol 1980; 56:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19304/abstract/61\">",
"      Schieve LA, Cogswell ME, Scanlon KS. An empiric evaluation of the Institute of Medicine's pregnancy weight gain guidelines by race. Obstet Gynecol 1998; 91:878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19304/abstract/62\">",
"      Langford A, Joshu C, Chang JJ, et al. Does gestational weight gain affect the risk of adverse maternal and infant outcomes in overweight women? Matern Child Health J 2011; 15:860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19304/abstract/63\">",
"      Nohr EA, Vaeth M, Baker JL, et al. Combined associations of prepregnancy body mass index and gestational weight gain with the outcome of pregnancy. Am J Clin Nutr 2008; 87:1750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19304/abstract/64\">",
"      Cedergren M. Effects of gestational weight gain and body mass index on obstetric outcome in Sweden. Int J Gynaecol Obstet 2006; 93:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19304/abstract/65\">",
"      Beyerlein A, Schiessl B, Lack N, von Kries R. Optimal gestational weight gain ranges for the avoidance of adverse birth weight outcomes: a novel approach. Am J Clin Nutr 2009; 90:1552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19304/abstract/66\">",
"      Jeric M, Roje D, Medic N, et al. Maternal pre-pregnancy underweight and fetal growth in relation to institute of medicine recommendations for gestational weight gain. Early Hum Dev 2012.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 441 Version 25.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-200.131.240.2-B6AD6E7C64-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_54_19304=[""].join("\n");
var outline_f18_54_19304=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H7\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CHANGE IN WEIGHT RELATED TO PREGNANCY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20253963\">",
"      Biologic factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20253941\">",
"      Other factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      RECOMMENDATIONS FOR WEIGHT GAIN DURING PREGNANCY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1230637565\">",
"      2009 IOM weight gain recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      OUTCOME OF 1990 IOM RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21938069\">",
"      EFFECT OF WEIGHT LOSS IN OBESE WOMEN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      COUNSELING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18139899\">",
"      Women of normal weight",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20254135\">",
"      Overweight and obese women",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20254142\">",
"      Underweight women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/441\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/441|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/54/2927\" title=\"table 1\">",
"      BMI table",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?18/50/19244\" title=\"table 2\">",
"      IOM weight and weight gain recommendations for pregnant women",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/38/7781?source=related_link\">",
"      Eating disorders in pregnant women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/21/20823?source=related_link\">",
"      Large for gestational age newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/44/28362?source=related_link\">",
"      Nutrition in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/30/39402?source=related_link\">",
"      Overview of postpartum care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/45/13016?source=related_link\">",
"      Overview of therapy for obesity in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?36/29/37331?source=related_link\">",
"      Patient information: Prenatal care (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/50/13094?source=related_link\">",
"      Physiology of leptin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/30/7657?source=related_link\">",
"      Recommendations for exercise during pregnancy and the postpartum period",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/23/9593?source=related_link\">",
"      Small for gestational age infant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/11/29882?source=related_link\">",
"      The impact of obesity on fertility and pregnancy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_54_19305="Overview of the medical management of mild to moderate Crohn's disease in adults";
var content_f18_54_19305=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of the medical management of mild to moderate Crohn's disease in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/54/19305/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/54/19305/contributors\">",
"     Richard J Farrell, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/54/19305/contributors\">",
"     Mark A Peppercorn, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/54/19305/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/54/19305/contributors\">",
"     Paul Rutgeerts, MD, PhD, FRCP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/54/19305/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/54/19305/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?18/54/19305/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 15, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Crohn's disease is an inflammatory condition of unknown etiology that can affect any portion of the gastrointestinal tract from the mouth to the perianal area. Its transmural inflammatory nature coupled with the variability of organ distribution gives rise to a spectrum of clinical presentations, each of which has to be considered separately in deciding upon the proper therapeutic approach. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/0/20490?source=see_link\">",
"     \"Clinical manifestations, diagnosis and prognosis of Crohn's disease in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Numerous therapies are used for the treatment of Crohn's disease. The choice of therapy will vary depending upon the anatomic location of disease, the severity of disease, and the goal of therapy (ie, induction or maintenance of remission). Medical therapies that are commonly used for Crohn's disease include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Oral 5-aminosalicylates (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"       sulfasalazine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/44/22215?source=see_link\">",
"       mesalamine",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Antibiotics (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"       ciprofloxacin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"       metronidazole",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Conventional glucocorticoids (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Non-systemic glucocorticoids (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/7/32880?source=see_link\">",
"       budesonide",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Immunomodulators (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      , 6-mercaptopurine,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Biologic therapies (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"       infliximab",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"       adalimumab",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This topic will provide an overview of the use of 5-aminosalicylates, antibiotics, and glucocorticoids for the treatment of Crohn's disease. The approach to patients with severe or refractory Crohn's disease, detailed discussions of individual medications, and other treatments for Crohn's disease are discussed separately:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/11/6329?source=see_link\">",
"       \"Overview of the medical management of severe or refractory Crohn's disease in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/55/20344?source=see_link\">",
"       \"Sulfasalazine and 5-aminosalicylates in the treatment of inflammatory bowel disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/34/20008?source=see_link\">",
"       \"Antibiotics for treatment of inflammatory bowel diseases\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/40/10886?source=see_link\">",
"       \"Budesonide in the treatment of Crohn's disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/31/7673?source=see_link\">",
"       \"Immunomodulator therapy in Crohn's disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/4/44105?source=see_link\">",
"       \"Infliximab in Crohn's disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/55/29559?source=see_link\">",
"       \"Adalimumab for treatment of Crohn's disease in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/2/33829?source=see_link\">",
"       \"Certolizumab pegol for treatment of Crohn's disease in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/22/3429?source=see_link\">",
"       \"Natalizumab for treatment of Crohn's disease in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/50/4906?source=see_link\">",
"       \"Surgical management of ulcerative colitis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/50/809?source=see_link\">",
"       \"Medical prophylaxis of postoperative Crohn's disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/34/17962?source=see_link\">",
"       \"Investigational therapies in the medical management of Crohn's disease\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11240437\">",
"    <span class=\"h1\">",
"     DEFINITIONS OF SEVERITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical trials of Crohn's disease often use formal grading systems to describe disease severity. Two commonly used systems are the Crohn's Disease Activity Index (CDAI) (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?5/61/6098?source=see_link\">",
"     calculator 1",
"    </a>",
"    ) and the Harvey-Bradshaw Index (HBI) (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?19/33/19985?source=see_link\">",
"     calculator 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/54/19305/abstract/1\">",
"     1",
"    </a>",
"    ], which is a simplified derivative of the CDAI. The HBI has been shown to correlate with the CDAI [",
"    <a class=\"abstract\" href=\"UTD.htm?18/54/19305/abstract/2\">",
"     2",
"    </a>",
"    ]. A drop in the CDAI of 100 points corresponds to a 3-point drop in the HBI. A CDAI of &lt;150 (clinical remission) corresponds to an HBI of &lt;4.",
"   </p>",
"   <p>",
"    The following working definitions may be more practical for clinical practice [",
"    <a class=\"abstract\" href=\"UTD.htm?18/54/19305/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Asymptomatic remission (CDAI &lt;150) &ndash; Patients who are asymptomatic either spontaneously or after medical or surgical intervention. Patients requiring steroids to remain asymptomatic are",
"      <strong>",
"       not",
"      </strong>",
"      considered to be in remission but are referred to as being \"steroid-dependent.\"",
"     </li>",
"     <li>",
"      Mild to moderate Crohn's disease (CDAI 150-220) &ndash; Ambulatory patients able to tolerate an oral diet without dehydration, toxicity, abdominal tenderness, mass, obstruction, or &gt;10 percent weight loss.",
"     </li>",
"     <li>",
"      Moderate to severe Crohn's disease (CDAI 220-450) &ndash; Patients who have failed treatment for mild to moderate disease or patients with prominent symptoms such as fever, weight loss, abdominal pain and tenderness, intermittent nausea or vomiting, or anemia.",
"     </li>",
"     <li>",
"      Severe-fulminant disease (CDAI &gt;450) &ndash; Patients with persisting symptoms despite conventional glucocorticoids or biologic agents (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"       infliximab",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"       adalimumab",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/6/39014?source=see_link\">",
"       certolizumab pegol",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/15/1271?source=see_link\">",
"       natalizumab",
"      </a>",
"      ) as outpatients, or individuals presenting with high fevers, persistent vomiting, intestinal obstruction, significant peritoneal signs, cachexia, or evidence of an abscess.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     STEP-UP VERSUS TOP-DOWN THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two general approaches to the treatment of mild to moderate Crohn's disease: step-up therapy and top-down therapy. Step-up therapy typically starts with medications that are less potent and (often) associated with fewer side effects. If those therapies are ineffective, more potent (and potentially more toxic) medications are used. Top-down therapy starts with more potent therapies, such as biologic therapy or immunomodulator therapy, relatively early in the course of the disease before patients become glucocorticoid dependent, and possibly even before they receive glucocorticoids. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/11/6329?source=see_link\">",
"     \"Overview of the medical management of severe or refractory Crohn's disease in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The relative merits of these strategies have not been extensively studied. One of the largest controlled trials included a total of 133 patients with newly diagnosed Crohn's disease who were randomly assigned to combined immunosuppression (with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    ) or conventional management with glucocorticoids followed by azathioprine and infliximab as needed [",
"    <a class=\"abstract\" href=\"UTD.htm?18/54/19305/abstract/4\">",
"     4",
"    </a>",
"    ]. Significantly more patients in the initial immunosuppression (top-down) group were in clinical remission at 26 weeks (60 versus 36 percent) and at 52 weeks (62 verus 42 percent). Serious adverse events were seen in a similar proportion of both groups (31 versus 25 percent).",
"   </p>",
"   <p>",
"    Given the heterogeneity of the disease and multiple options for combining therapy, it is unlikely that sufficient controlled trials will ever become available to guide treatment for every clinical circumstance. In addition, the cost of therapy, patient compliance, and individual susceptibility to drug toxicity are equally relevant factors for making decisions at the bedside.",
"   </p>",
"   <p>",
"    As a general rule, we favor step-up therapy, beginning treatment with less potent drugs that have relatively long track records and good safety profiles. We then progress to more potent treatments in patients with severe or refractory disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/11/6329?source=see_link\">",
"     \"Overview of the medical management of severe or refractory Crohn's disease in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11241188\">",
"    <span class=\"h1\">",
"     TREATMENT OF ACTIVE DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Outpatient therapy with oral medications is appropriate for most patients with mildly to moderately active Crohn's disease. However, hospitalization is required for patients who present with severe symptoms or who appear toxic. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/11/6329?source=see_link\">",
"     \"Overview of the medical management of severe or refractory Crohn's disease in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients with mild to moderate Crohn's disease, treatment will in part depend upon the site of disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Oral lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aphthous ulcerations are the most common oral manifestation of Crohn's disease. A wide variety of additional lesions have been described, including granulomatous masses, cheilitis, and granulomatous sialadenitis. These abnormalities can be severe and may dominate the clinical picture by causing enough pain to impair nutrition. They usually occur with coexistent intestinal disease and respond to treatment directed at the intestinal disease. Topical medications, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/38/39520?source=see_link\">",
"     triamcinolone",
"    </a>",
"    acetonide in Orabase, can provide local symptom relief. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/11/25786?source=see_link&amp;anchor=H19#H19\">",
"     \"Oral lesions\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Gastroduodenal Crohn's disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fewer than 5 percent of patients with Crohn's disease have gastroduodenal disease, most often in association with concurrent distal intestinal involvement. The distal antrum and duodenum are most commonly affected.",
"   </p>",
"   <p>",
"    The clinical presentation is often confused with that of peptic ulcer disease and symptoms may include epigastric pain, nausea, and postprandial vomiting. Treatment with a proton pump inhibitor, H2 receptor antagonist, or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/29/29141?source=see_link\">",
"     sucralfate",
"    </a>",
"    may provide partial or complete relief of symptoms. The slow release form of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/44/22215?source=see_link\">",
"     mesalamine",
"    </a>",
"    encapsulated in ethylcellulose microgranules (Pentasa&reg;) is partially released in the proximal small bowel and theoretically may be of use in duodenal Crohn's disease. There are, however, no clinical trials to confirm its efficacy in this setting.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     Prednisone",
"    </a>",
"    is necessary and usually effective for most patients with moderate to severe gastroduodenal disease. In one report of 89 patients, 45 of the 49 patients (92 percent) treated medically had a good to excellent response [",
"    <a class=\"abstract\" href=\"UTD.htm?18/54/19305/abstract/5\">",
"     5",
"    </a>",
"    ]. Thirty-three patients required surgery, usually for gastroduodenal obstruction. The response to therapy is usually seen within two weeks, but the duration of response is variable. We usually suggest",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    or 6-mercaptopurine in patients who remain symptomatic despite a course of prednisone or who become steroid-dependent. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Conventional glucocorticoids'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/11/6329?source=see_link&amp;anchor=H11188258#H11188258\">",
"     \"Overview of the medical management of severe or refractory Crohn's disease in adults\", section on 'Azathioprine and 6-mercaptopurine'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Ileitis and colitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ileum is the region of the small bowel most commonly involved in Crohn's disease. Patients with active ileitis typically present with diarrhea and abdominal pain; they can also have weight loss (usually related to decreased oral intake), low-grade fever, and anemia. Patients with active ileocolitis or Crohn's disease limited to the colon may present with abdominal pain, bloody or nonbloody diarrhea, fever, and weight loss. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/0/20490?source=see_link\">",
"     \"Clinical manifestations, diagnosis and prognosis of Crohn's disease in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients with mild to moderate disease, we usually begin therapy with oral 5-aminosalicylates (5-ASA) drugs, though, as noted below, experts disagree about the efficacy of 5-ASA drugs for Crohn's disease. We then progress to treatment with antibiotics, glucocorticoids, and immunosuppressive agents depending upon the response (",
"    <a class=\"graphic graphic_algorithm graphicRef61081 \" href=\"UTD.htm?20/4/20558\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The optimal management of patients who are asymptomatic or minimally symptomatic is unclear. Some data suggest that the use of 5-ASA drugs may decrease the risk of colon cancer. As a result, we typically suggest treatment with a 5-ASA drug for such patients if their Crohn's disease involves the colon. However, whether any treatment alters the natural history of the disease in such patients is unproven. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/55/20344?source=see_link&amp;anchor=H194953227#H194953227\">",
"     \"Sulfasalazine and 5-aminosalicylates in the treatment of inflammatory bowel disease\", section on '5-ASA formulations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     5-ASA drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of 5-ASA drugs for Crohn's disease is controversial. Studies evaluating the efficacy of 5-ASA drugs in Crohn's disease have produced mixed results:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A 2011 meta-analysis examined the role of 5-ASAs in patients with Crohn's disease for both induction of remission and maintenance of remission [",
"      <a class=\"abstract\" href=\"UTD.htm?18/54/19305/abstract/6\">",
"       6",
"      </a>",
"      ]. The meta-analysis included 22 randomized trials (6 trials looking at 5-ASAs for the induction of remission, 13 for maintenance of remission, and 3 for both induction and maintenance of remission). The meta-analysis found that:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      5-ASAs taken as a group were superior to placebo for the induction of remission. Failure to achieve remission was seen in 68 percent of patients treated with 5-ASAs compared with 75 percent of patients treated with placebo (relative risk [RR] 0.89; 95% CI 0.80-0.99). The study found that in order to achieve remission in one patient with active Crohn's disease, 11 patients would need to be treated.",
"      <br/>",
"      <br/>",
"      There was no significant benefit in remission rates when only trials using",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/44/22215?source=see_link\">",
"       mesalamine",
"      </a>",
"      were examined. Similarly, when studies using",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"       sulfasalazine",
"      </a>",
"      were examined, the benefit was of borderline statistical significance (RR 0.83; 95% CI 0.69-1.00, p = 0.05). However, higher doses of mesalamine (&ge;1.5",
"      <span class=\"nowrap\">",
"       g/day)",
"      </span>",
"      were associated with achieving a combined endpoint of remission or symptom improvement (RR 0.96; 95% CI 0.48-.098, number needed to treat [NNT] of 6).",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"       Sulfasalazine",
"      </a>",
"      plus a glucocorticoid was not superior to a glucocorticoid alone for the induction of remission.",
"     </li>",
"     <li>",
"      One trial compared",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/3/43059?source=see_link\">",
"       olsalazine",
"      </a>",
"      with placebo and found olsalazine to be inferior to placebo (RR of failure to improve 1.62; 95% CI 1.18-2.21).",
"     </li>",
"     <li>",
"      There was no benefit with 5-ASA treatment for the maintenance of remission. Patients treated with 5-ASAs had a relapse rate of 56 percent compared with 57 percent for patients who received placebo.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Additional findings from a 2010 meta-analysis of 19 randomized trials included:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"       Sulfasalazine",
"      </a>",
"      was more likely to induce remission than placebo (RR 1.38; 95% CI 1.02-1.87), with the benefit being confined primarily to patients with colitis.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"       Sulfasalazine",
"      </a>",
"      was inferior to glucocorticoids for inducing remission (RR 0.66, 95% CI 0.53-0.81).",
"     </li>",
"     <li>",
"      Neither low-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/44/22215?source=see_link\">",
"       mesalamine",
"      </a>",
"      (1 to 2",
"      <span class=\"nowrap\">",
"       g/day)",
"      </span>",
"      nor high-dose mesalamine (3 to 4.5",
"      <span class=\"nowrap\">",
"       g/day)",
"      </span>",
"      was superior to placebo for induction of remission.",
"     </li>",
"     <li>",
"      5-ASAs were inferior to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/7/32880?source=see_link\">",
"       budesonide",
"      </a>",
"      (RR 0.56; 95% CI 0.40-0.78) in one trial.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A 2011 meta-analysis with six trials specifically looked at the use of 5-ASA drugs for the maintenance of remission [",
"      <a class=\"abstract\" href=\"UTD.htm?18/54/19305/abstract/6\">",
"       6",
"      </a>",
"      ]. In that analysis, there was a trend toward a benefit with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"       sulfasalazine",
"      </a>",
"      compared with placebo, but there was no definite benefit of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/44/22215?source=see_link\">",
"       mesalamine",
"      </a>",
"      compared with placebo.",
"     </li>",
"     <li>",
"      In a 2011 study that was not included in the above meta-analyses,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/44/22215?source=see_link\">",
"       mesalamine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/7/32880?source=see_link\">",
"       budesonide",
"      </a>",
"      were similarly effective for the induction of remission in patients with mildly to moderately active Crohn's disease [",
"      <a class=\"abstract\" href=\"UTD.htm?18/54/19305/abstract/7\">",
"       7",
"      </a>",
"      ]. Three hundred nine patients were assigned to receive budesonide 9",
"      <span class=\"nowrap\">",
"       mg/day,",
"      </span>",
"      budesonide 3 mg three times per day, or Eudragit-L-coated mesalamine 4.5",
"      <span class=\"nowrap\">",
"       g/day.",
"      </span>",
"      The remission rates were similar between those who received budesonide and those who received mesalamine (70 versus 62 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The uncertainty about the benefit of 5-ASA drugs is reflected in variable guidelines from gastroenterology societies and recommendations from experts.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Practice Parameters Committee of the American College of Gastroenterology and the British Society of Gastroenterology both recommend 5-ASA drugs for use as first-line therapy in patients with mildly to moderately active Crohn's disease [",
"      <a class=\"abstract\" href=\"UTD.htm?18/54/19305/abstract/8,9\">",
"       8,9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The European Crohn's and Colitis Organization Consensus recommends that 5-ASAs not be used for Crohn's disease [",
"      <a class=\"abstract\" href=\"UTD.htm?18/54/19305/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Some experts recommend that 5-ASA drugs other than",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"       sulfasalazine",
"      </a>",
"      not be used in the treatment of Crohn's disease for either induction or maintenance of remission. However, sulfasalazine (3 to 6",
"      <span class=\"nowrap\">",
"       g/day",
"      </span>",
"      over a course of 16 weeks) may be an option in patients with mild to moderate colonic (left-sided) Crohn's disease [",
"      <a class=\"abstract\" href=\"UTD.htm?18/54/19305/abstract/11-13\">",
"       11-13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      By contrast, we and others argue that 5-ASAs should be tried in patients with mild Crohn's disease based upon their relative safety compared with glucocorticoids, immunomodulators, and biologic agents, particularly given the potential chemopreventative benefits of 5-ASAs in patients with longstanding Crohn's colitis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For patients with ileitis and mild symptoms, we often begin treatment with a slow release oral 5-ASA drug (",
"    <a class=\"graphic graphic_table graphicRef56444 \" href=\"UTD.htm?22/12/22733\">",
"     table 1",
"    </a>",
"    ), such as Pentasa&reg; (2",
"    <span class=\"nowrap\">",
"     g/day)",
"    </span>",
"    or Asacol&reg; (2.4",
"    <span class=\"nowrap\">",
"     g/day).",
"    </span>",
"    The dose is then increased to a maximum of 4",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    for Pentasa&reg; or 4.8",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    for Asacol&reg;, depending upon the clinical response. By contrast,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    is less useful for ileitis because colonic bacteria must cleave the drug to release the active 5-ASA moiety.",
"   </p>",
"   <p>",
"    For patients with ileocolitis or colitis and mild to moderate symptoms, we initiate therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    (2",
"    <span class=\"nowrap\">",
"     g/day)",
"    </span>",
"    or one of the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/44/22215?source=see_link\">",
"     mesalamine",
"    </a>",
"    drugs (2 to 2.4",
"    <span class=\"nowrap\">",
"     g/day,",
"    </span>",
"    depending upon the drug used) (",
"    <a class=\"graphic graphic_table graphicRef56444 \" href=\"UTD.htm?22/12/22733\">",
"     table 1",
"    </a>",
"    ). Again, the doses of the medications are increased based upon the patient's clinical response.",
"   </p>",
"   <p>",
"    Side effects of these medications include nausea, headache, fever, rash, pancreatitis, and pneumonitis (",
"    <a class=\"graphic graphic_table graphicRef64059 \" href=\"UTD.htm?2/22/2412\">",
"     table 2",
"    </a>",
"    ) and are more common with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/55/20344?source=see_link&amp;anchor=H11#H11\">",
"     \"Sulfasalazine and 5-aminosalicylates in the treatment of inflammatory bowel disease\", section on 'Side effects'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest antibiotics in patients who do not tolerate 5-ASAs or do not improve within three to four weeks of starting a 5-ASA. It is unclear if the efficacy of antimicrobial therapy is due to treatment of an undetected pathogen, bacterial overgrowth, or an unsuspected microperforation. Specific recommendations and supporting data for antibiotics in Crohn's disease are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/34/20008?source=see_link\">",
"     \"Antibiotics for treatment of inflammatory bowel diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Conventional glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral glucocorticoids continue to be a mainstay of treatment for patients with mild to moderate disease who are unresponsive to the above measures, or for those presenting with more severe initial symptoms (but who are not so ill that they require hospitalization and intravenous glucocorticoids) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/54/19305/abstract/11,14,15\">",
"     11,14,15",
"    </a>",
"    ]. A 2011 meta-analysis failed to show a statistically significant benefit with glucocorticoids compared with placebo for the induction of remission due to heterogeneity between the included studies (RR of failure to achieve remission 0.46, 95% CI 0.17-1.28). However, the individual studies included in the analysis both showed a benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?18/54/19305/abstract/11,14\">",
"     11,14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The initial dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    is 40 to 60",
"    <span class=\"nowrap\">",
"     mg/day.",
"    </span>",
"    Sixty to 80 percent of patients will respond to this dose, usually within 10 to 14 days. At that point, a gradual tapering by 5",
"    <span class=\"nowrap\">",
"     mg/week",
"    </span>",
"    should be considered with the definite goal of discontinuing the prednisone. Glucocorticoids should not be used long-term due to significant side effects. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=see_link\">",
"     \"Major side effects of systemic glucocorticoids\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    5-ASA drugs and antibiotics can be used concomitantly with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    . One controlled trial demonstrated that the combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    and prednisone was better than either alone [",
"    <a class=\"abstract\" href=\"UTD.htm?18/54/19305/abstract/14\">",
"     14",
"    </a>",
"    ], though not all studies have shown a benefit with combination therapy (see",
"    <a class=\"local\" href=\"#H7\">",
"     '5-ASA drugs'",
"    </a>",
"    above). Once remission is achieved and the prednisone tapered and stopped, maintenance therapy with an oral 5-ASA drug at a dose of 3 to 3.6",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    (depending upon the drug chosen) should be considered (",
"    <a class=\"graphic graphic_table graphicRef56444 \" href=\"UTD.htm?22/12/22733\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H4038653\">",
"     'Maintenance therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11242861\">",
"    <span class=\"h3\">",
"     Non-systemic glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Controlled ileal release (CIR)",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/7/32880?source=see_link\">",
"     budesonide",
"    </a>",
"    is a glucocorticoid with a high first-pass hepatic metabolism that may be used as an alternative to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    for patients with active ileitis or right-sided Crohn's colitis, particularly in those with prior intolerance or contraindications to systemic glucocorticoids. Systemic side effects are seen to a lesser extent with budesonide than with conventional glucocorticoids. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/40/10886?source=see_link\">",
"     \"Budesonide in the treatment of Crohn's disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Placebo-controlled trials have demonstrated that CIR",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/7/32880?source=see_link\">",
"     budesonide",
"    </a>",
"    9",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    is effective in patients with mildly to moderately active Crohn's ileitis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    right colon involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?18/54/19305/abstract/16\">",
"     16",
"    </a>",
"    ]. While CIR budesonide is somewhat less effective than standard glucocorticoids for inducing remission, it is associated with significantly fewer glucocorticoid-associated side effects [",
"    <a class=\"abstract\" href=\"UTD.htm?18/54/19305/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. CIR budesonide is used at a dose of 9",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    for 8 to 16 weeks and then tapered by 3 mg increments over two to four weeks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Antidiarrheal medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptomatic treatment with antidiarrheal drugs should be considered in patients not responding completely to first-line therapy. We suggest",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/53/16214?source=see_link\">",
"     loperamide",
"    </a>",
"    because of its efficacy and relative safety [",
"    <a class=\"abstract\" href=\"UTD.htm?18/54/19305/abstract/18\">",
"     18",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/33/36374?source=see_link\">",
"     Cholestyramine",
"    </a>",
"    is another consideration for patients with non-stenosing ileitis who have chronic watery diarrhea. It is also indicated for patients with previous ileal resections who have bile salt diarrhea. The initial dose is 4",
"    <span class=\"nowrap\">",
"     g/day,",
"    </span>",
"    which is increased as needed to 12",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    in three divided doses. For patients intolerant of cholestyramine because of dyspepsia,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/26/12710?source=see_link\">",
"     colestipol",
"    </a>",
"    , a similar binding resin, is often a suitable alternative. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/14/42217?source=see_link\">",
"     \"Lipid lowering with drugs other than statins and fibrates\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4038575\">",
"    <span class=\"h3\">",
"     Probiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Probiotics are viable microorganisms with beneficial physiologic or therapeutic activities. Limited clinical trials suggest that selected probiotic species, alone or in combination, can prevent recurrent intestinal inflammation and possibly treat active inflammatory bowel disease. The best results have been observed in patients with pouchitis, while mixed results have been reported in other settings. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/10/16554?source=see_link\">",
"     \"Probiotics for gastrointestinal diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11242907\">",
"    <span class=\"h3\">",
"     Lactose avoidance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with Crohn's disease, particularly those with ileal disease, have an increased frequency of acquired",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/62/14306?source=see_link\">",
"     lactase",
"    </a>",
"    deficiency and symptomatic lactose intolerance [",
"    <a class=\"abstract\" href=\"UTD.htm?18/54/19305/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. Patients with suggestive symptoms should undergo a trial of lactose avoidance. If the diagnosis is in doubt, a lactose breath hydrogen test can be obtained. If the patient responds to lactose avoidance or if the test is positive, the patient should be instructed to avoid lactose containing foods (",
"    <a class=\"graphic graphic_table graphicRef54826 \" href=\"UTD.htm?35/25/36252\">",
"     table 3",
"    </a>",
"    ). Calcium supplementation should be maintained in patients on a limited lactose intake to minimize the risk of bone loss. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/32/5641?source=see_link\">",
"     \"Lactose intolerance\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4038499\">",
"    <span class=\"h3\">",
"     Other dietary interventions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dietary interventions in patients with Crohn's disease aim to improve nutrition and eliminate food triggers. This topic is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/7/44152?source=see_link\">",
"     \"Nutrition and dietary interventions in adults with inflammatory bowel disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11240616\">",
"    <span class=\"h2\">",
"     Perianal disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Perianal abscesses and fistulae occur in up to one-third of patients with Crohn's disease. The management of such patients is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/43/25273?source=see_link\">",
"     \"Perianal complications of Crohn's disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4038653\">",
"    <span class=\"h1\">",
"     MAINTENANCE THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once a patient has achieved remission using a 5-ASA drug, antibiotics,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a glucocorticoid, we suggest maintenance therapy with a 5-ASA drug. In patients with ileal disease,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/44/22215?source=see_link\">",
"     mesalamine",
"    </a>",
"    (Pentasa&reg;, Asacol&reg;) at a dose of 3 to 3.6",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    should be considered as long-term therapy, with the hope of preventing disease relapse [",
"    <a class=\"abstract\" href=\"UTD.htm?18/54/19305/abstract/21-24\">",
"     21-24",
"    </a>",
"    ]. However, it must be acknowledged that there is inconsistent evidence supporting this approach. (See",
"    <a class=\"local\" href=\"#H7\">",
"     '5-ASA drugs'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/55/20344?source=see_link&amp;anchor=H194953227#H194953227\">",
"     \"Sulfasalazine and 5-aminosalicylates in the treatment of inflammatory bowel disease\", section on '5-ASA formulations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Limited data also suggest that antibiotics are effective for the maintenance of remission [",
"    <a class=\"abstract\" href=\"UTD.htm?18/54/19305/abstract/25\">",
"     25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/34/20008?source=see_link&amp;anchor=H2#H2\">",
"     \"Antibiotics for treatment of inflammatory bowel diseases\", section on 'Crohn's disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/7/32880?source=see_link\">",
"     Budesonide",
"    </a>",
"    may be effective for the short-term maintenance of remission (three to six months), but studies suggest it is not effective for long-term maintenance [",
"    <a class=\"abstract\" href=\"UTD.htm?18/54/19305/abstract/16\">",
"     16",
"    </a>",
"    ]. Conventional glucocorticoids are not effective for preventing relapses in patients in remission [",
"    <a class=\"abstract\" href=\"UTD.htm?18/54/19305/abstract/3,26,27\">",
"     3,26,27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/40/10886?source=see_link\">",
"     \"Budesonide in the treatment of Crohn's disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11188929\">",
"    <span class=\"h1\">",
"     REFRACTORY CROHN'S DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with Crohn's disease who relapse while on treatment, who fail to respond to the above treatments, or who cannot be successfully tapered off of steroids may require treatment with immunomodulators or biologic therapy. The management of these patients is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/11/6329?source=see_link\">",
"     \"Overview of the medical management of severe or refractory Crohn's disease in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H348325067\">",
"    <span class=\"h1\">",
"     OTHER MANAGEMENT ISSUES",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is important to consider routine health maintenance, including screening and prevention of other diseases as well as monitoring for side effects of therapy in patients with inflammatory bowel disease (IBD) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/54/19305/abstract/28-30\">",
"     28-30",
"    </a>",
"    ]. These issues are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/36/22090?source=see_link&amp;anchor=H110252836#H110252836\">",
"     \"Management of mild to moderate ulcerative colitis\", section on 'Other management issues'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?9/56/10115?source=see_link\">",
"       \"Patient information: Crohn's disease in adults (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?23/40/24196?source=see_link\">",
"       \"Patient information: Crohn's disease (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?17/11/17586?source=see_link\">",
"       \"Patient information: Sulfasalazine and the 5-aminosalicylates (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Outpatient therapy with oral medications is appropriate for most patients with mildly to moderately active Crohn's disease. However, hospitalization is required for patients who present with severe symptoms or who appear toxic. (See",
"      <a class=\"local\" href=\"#H11241188\">",
"       'Treatment of active disease'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/11/6329?source=see_link&amp;anchor=H11189921#H11189921\">",
"       \"Overview of the medical management of severe or refractory Crohn's disease in adults\", section on 'Severe disease'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      There are two general approaches to the outpatient treatment of Crohn's disease: step-up therapy and top-down therapy. Step-up therapy typically starts with medications that are less potent and (often) associated with fewer side effects. If those therapies are ineffective, more potent (and potentially more toxic) medications are used. Top-down therapy starts with more potent therapies, such as biologic therapy or immunomodulator therapy, relatively early in the course of the disease. In general, we favor step-up therapy. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Step-up versus top-down therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest an initial trial of 5-aminosalycilic acid (5-ASA) drugs in patients with mild to moderate Crohn's disease who do not have systemic symptoms rather than treatment with glucocorticoids, immunomodulators, or biologic therapies (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). This suggestion is based upon the relative safety of 5-ASAs compared with the other drugs. However, data supporting the use of 5-ASA drugs are variable and some authorities recommend that 5-ASA drugs (with the possible exception of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"       sulfasalazine",
"      </a>",
"      ) not be used in the treatment of Crohn's disease. (See",
"      <a class=\"local\" href=\"#H7\">",
"       '5-ASA drugs'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      For patients with ileitis and mild symptoms, we often begin treatment with a slow release oral 5-ASA drug (",
"      <a class=\"graphic graphic_table graphicRef56444 \" href=\"UTD.htm?22/12/22733\">",
"       table 1",
"      </a>",
"      ), such as Pentasa&reg; (2",
"      <span class=\"nowrap\">",
"       g/day)",
"      </span>",
"      or Asacol&reg; (2.4",
"      <span class=\"nowrap\">",
"       g/day).",
"      </span>",
"      The dose is then increased to a maximum of 4",
"      <span class=\"nowrap\">",
"       g/day",
"      </span>",
"      for Pentasa&reg; or 4.8",
"      <span class=\"nowrap\">",
"       g/day",
"      </span>",
"      for Asacol&reg;, depending upon the clinical response. By contrast, sulfasalazine is less useful for ileitis because colonic bacteria must cleave the drug to release the active 5-ASA moiety.",
"      <br/>",
"      <br/>",
"      For patients with ileocolitis or colitis and mild to moderate symptoms, we initiate therapy with sulfasalazine (2",
"      <span class=\"nowrap\">",
"       g/day)",
"      </span>",
"      or one of the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/44/22215?source=see_link\">",
"       mesalamine",
"      </a>",
"      drugs (2 to 2.4",
"      <span class=\"nowrap\">",
"       g/day,",
"      </span>",
"      depending upon the drug used) (",
"      <a class=\"graphic graphic_table graphicRef56444 \" href=\"UTD.htm?22/12/22733\">",
"       table 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      We suggest antibiotics (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"       ciprofloxacin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"       metronidazole",
"      </a>",
"      ) in patients who do not tolerate 5-ASA drugs or do not improve within three to four weeks (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/34/20008?source=see_link\">",
"       \"Antibiotics for treatment of inflammatory bowel diseases\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We suggest",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      40 to 60",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      for patients with mild to moderate disease who are unresponsive to the above measures, or for those presenting with more severe initial symptoms (but not requiring hospitalization) (",
"      <a class=\"grade\" href=\"._grade_4?title=Grade 2A\">",
"       Grade 2A",
"      </a>",
"      ). Controlled ileal release (CIR)",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/7/32880?source=see_link\">",
"       budesonide",
"      </a>",
"      is a glucocorticoid with a high first-pass hepatic metabolism that is a reasonable alternative to prednisone for patients with active ileitis or right-sided Crohn's colitis, particularly in those with prior intolerance or contraindications to systemic glucocorticoids. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Conventional glucocorticoids'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/11/6329?source=see_link&amp;anchor=H11189921#H11189921\">",
"       \"Overview of the medical management of severe or refractory Crohn's disease in adults\", section on 'Severe disease'",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H11242861\">",
"       'Non-systemic glucocorticoids'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest maintenance therapy with a 5-ASA drug rather than",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/7/32880?source=see_link\">",
"       budesonide",
"      </a>",
"      or no treatment for patients who have achieved remission with a 5-ASA drug, antibiotics,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      glucocorticoids (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4038653\">",
"       'Maintenance therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with refractory disease may require treatment with immunomodulators or biologic therapy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/11/6329?source=see_link\">",
"       \"Overview of the medical management of severe or refractory Crohn's disease in adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19305/abstract/1\">",
"      Harvey RF, Bradshaw JM. A simple index of Crohn's-disease activity. Lancet 1980; 1:514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19305/abstract/2\">",
"      Vermeire S, Schreiber S, Sandborn WJ, et al. Correlation between the Crohn's disease activity and Harvey-Bradshaw indices in assessing Crohn's disease severity. Clin Gastroenterol Hepatol 2010; 8:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19305/abstract/3\">",
"      Lichtenstein GR, Hanauer SB, Sandborn WJ, Practice Parameters Committee of American College of Gastroenterology. Management of Crohn's disease in adults. Am J Gastroenterol 2009; 104:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19305/abstract/4\">",
"      D'Haens G, Baert F, van Assche G, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 2008; 371:660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19305/abstract/5\">",
"      Nugent FW, Roy MA. Duodenal Crohn's disease: an analysis of 89 cases. Am J Gastroenterol 1989; 84:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19305/abstract/6\">",
"      Ford AC, Kane SV, Khan KJ, et al. Efficacy of 5-aminosalicylates in Crohn's disease: systematic review and meta-analysis. Am J Gastroenterol 2011; 106:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19305/abstract/7\">",
"      Tromm A, Bungani I, Tomsov&aacute; E, et al. Budesonide 9 mg is at least as effective as mesalamine 4.5 g in patients with mildly to moderately active Crohn's disease. Gastroenterology 2011; 140:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19305/abstract/8\">",
"      Hanauer SB, Sandborn W, Practice Parameters Committee of the American College of Gastroenterology. Management of Crohn's disease in adults. Am J Gastroenterol 2001; 96:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19305/abstract/9\">",
"      Carter MJ, Lobo AJ, Travis SP, IBD Section, British Society of Gastroenterology. Guidelines for the management of inflammatory bowel disease in adults. Gut 2004; 53 Suppl 5:V1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19305/abstract/10\">",
"      Travis SP, Stange EF, L&eacute;mann M, et al. European evidence based consensus on the diagnosis and management of Crohn's disease: current management. Gut 2006; 55 Suppl 1:i16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19305/abstract/11\">",
"      Summers RW, Switz DM, Sessions JT Jr, et al. National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology 1979; 77:847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19305/abstract/12\">",
"      Van Hees PA, Van Lier HJ, Van Elteren PH, et al. Effect of sulphasalazine in patients with active Crohn's disease: a controlled double-blind study. Gut 1981; 22:404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19305/abstract/13\">",
"      Sandborn WJ, Feagan BG, Lichtenstein GR. Medical management of mild to moderate Crohn's disease: evidence-based treatment algorithms for induction and maintenance of remission. Aliment Pharmacol Ther 2007; 26:987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19305/abstract/14\">",
"      Malchow H, Ewe K, Brandes JW, et al. European Cooperative Crohn's Disease Study (ECCDS): results of drug treatment. Gastroenterology 1984; 86:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19305/abstract/15\">",
"      Benchimol EI, Seow CH, Steinhart AH, Griffiths AM. Traditional corticosteroids for induction of remission in Crohn's disease. Cochrane Database Syst Rev 2008; :CD006792.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19305/abstract/16\">",
"      Ford AC, Bernstein CN, Khan KJ, et al. Glucocorticosteroid therapy in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol 2011; 106:590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19305/abstract/17\">",
"      Rutgeerts P, L&ouml;fberg R, Malchow H, et al. A comparison of budesonide with prednisolone for active Crohn's disease. N Engl J Med 1994; 331:842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19305/abstract/18\">",
"      Barrett KE, Dharmsathaphorn K. Pharmacological aspects of therapy in inflammatory bowel diseases: antidiarrheal agents. J Clin Gastroenterol 1988; 10:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19305/abstract/19\">",
"      Perkal MF, Seashore JH. Nutrition and inflammatory bowel disease. Gastroenterol Clin North Am 1989; 18:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19305/abstract/20\">",
"      Mishkin B, Yalovsky M, Mishkin S. Increased prevalence of lactose malabsorption in Crohn's disease patients at low risk for lactose malabsorption based on ethnic origin. Am J Gastroenterol 1997; 92:1148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19305/abstract/21\">",
"      Messori A, Brignola C, Trallori G, et al. Effectiveness of 5-aminosalicylic acid for maintaining remission in patients with Crohn's disease: a meta-analysis. Am J Gastroenterol 1994; 89:692.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19305/abstract/22\">",
"      Steinhart AH, Hemphill D, Greenberg GR. Sulfasalazine and mesalazine for the maintenance therapy of Crohn's disease: a meta-analysis. Am J Gastroenterol 1994; 89:2116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19305/abstract/23\">",
"      Sutherland LR, Martin F, Bailey RJ, et al. A randomized, placebo-controlled, double-blind trial of mesalamine in the maintenance of remission of Crohn's disease. The Canadian Mesalamine for Remission of Crohn's Disease Study Group. Gastroenterology 1997; 112:1069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19305/abstract/24\">",
"      Prantera C, Pallone F, Brunetti G, et al. Oral 5-aminosalicylic acid (Asacol) in the maintenance treatment of Crohn's disease. The Italian IBD Study Group. Gastroenterology 1992; 103:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19305/abstract/25\">",
"      Khan KJ, Ullman TA, Ford AC, et al. Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol 2011; 106:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19305/abstract/26\">",
"      Dignass A, Van Assche G, Lindsay JO, et al. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management. J Crohns Colitis 2010; 4:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19305/abstract/27\">",
"      Steinhart AH, Ewe K, Griffiths AM, et al. Corticosteroids for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev 2003; :CD000301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19305/abstract/28\">",
"      Selby L, Kane S, Wilson J, et al. Receipt of preventive health services by IBD patients is significantly lower than by primary care patients. Inflamm Bowel Dis 2008; 14:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19305/abstract/29\">",
"      Sinclair JA, Wasan SK, Farraye FA. Health maintenance in the inflammatory bowel disease patient. Gastroenterol Clin North Am 2012; 41:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19305/abstract/30\">",
"      Wasan SK, Baker SE, Skolnik PR, Farraye FA. A practical guide to vaccinating the inflammatory bowel disease patient. Am J Gastroenterol 2010; 105:1231.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4069 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-58.240.98.179-4838B967EE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_54_19305=[""].join("\n");
var outline_f18_54_19305=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H34\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11240437\">",
"      DEFINITIONS OF SEVERITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      STEP-UP VERSUS TOP-DOWN THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11241188\">",
"      TREATMENT OF ACTIVE DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Oral lesions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Gastroduodenal Crohn's disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Ileitis and colitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - 5-ASA drugs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Antibiotics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Conventional glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11242861\">",
"      - Non-systemic glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Antidiarrheal medications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4038575\">",
"      - Probiotics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11242907\">",
"      - Lactose avoidance",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4038499\">",
"      - Other dietary interventions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11240616\">",
"      Perianal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4038653\">",
"      MAINTENANCE THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11188929\">",
"      REFRACTORY CROHN'S DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H348325067\">",
"      OTHER MANAGEMENT ISSUES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/4069\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/4069|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?20/4/20558\" title=\"algorithm 1\">",
"      Overview of the medical therapy of Crohns disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/4069|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?22/12/22733\" title=\"table 1\">",
"      Rx inflammatory bowel",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/22/2412\" title=\"table 2\">",
"      Side effects of sulfasalazine and aminosalicylates",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?35/25/36252\" title=\"table 3\">",
"      Lactose content",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?5/61/6098?source=related_link\" title=\"calculator 1\">",
"      Calculator: Crohn's disease activity index (CDAI)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?19/33/19985?source=related_link\" title=\"calculator 2\">",
"      Calculator: Harvey-Bradshaw index of Crohn's disease activity",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/55/29559?source=related_link\">",
"      Adalimumab for treatment of Crohn's disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/34/20008?source=related_link\">",
"      Antibiotics for treatment of inflammatory bowel diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/40/10886?source=related_link\">",
"      Budesonide in the treatment of Crohn's disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/2/33829?source=related_link\">",
"      Certolizumab pegol for treatment of Crohn's disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/0/20490?source=related_link\">",
"      Clinical manifestations, diagnosis and prognosis of Crohn's disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/31/7673?source=related_link\">",
"      Immunomodulator therapy in Crohn's disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/4/44105?source=related_link\">",
"      Infliximab in Crohn's disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/34/17962?source=related_link\">",
"      Investigational therapies in the medical management of Crohn's disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/32/5641?source=related_link\">",
"      Lactose intolerance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/14/42217?source=related_link\">",
"      Lipid lowering with drugs other than statins and fibrates",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=related_link\">",
"      Major side effects of systemic glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/36/22090?source=related_link\">",
"      Management of mild to moderate ulcerative colitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/50/809?source=related_link\">",
"      Medical prophylaxis of postoperative Crohn's disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/22/3429?source=related_link\">",
"      Natalizumab for treatment of Crohn's disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/7/44152?source=related_link\">",
"      Nutrition and dietary interventions in adults with inflammatory bowel disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/11/25786?source=related_link\">",
"      Oral lesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/11/6329?source=related_link\">",
"      Overview of the medical management of severe or refractory Crohn's disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?23/40/24196?source=related_link\">",
"      Patient information: Crohn's disease (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?9/56/10115?source=related_link\">",
"      Patient information: Crohn's disease in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?17/11/17586?source=related_link\">",
"      Patient information: Sulfasalazine and the 5-aminosalicylates (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/43/25273?source=related_link\">",
"      Perianal complications of Crohn's disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/10/16554?source=related_link\">",
"      Probiotics for gastrointestinal diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/55/20344?source=related_link\">",
"      Sulfasalazine and 5-aminosalicylates in the treatment of inflammatory bowel disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/50/4906?source=related_link\">",
"      Surgical management of ulcerative colitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_54_19306="Causes and diagnosis of membranous nephropathy";
var content_f18_54_19306=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Causes and diagnosis of membranous nephropathy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/54/19306/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/54/19306/contributors\">",
"     Laurence H Beck, Jr, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/54/19306/contributors\">",
"     David J Salant, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/54/19306/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/54/19306/contributors\">",
"     Richard J Glassock, MD, MACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/54/19306/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/54/19306/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?18/54/19306/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 12, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Membranous nephropathy (MN) is among the most common causes of the nephrotic syndrome in nondiabetic adults, accounting for up to one-third of biopsy diagnoses in some regions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/18/32041?source=see_link&amp;anchor=H2#H2\">",
"     \"Overview of heavy proteinuria and the nephrotic syndrome\", section on 'Etiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The term MN reflects the primary histologic change noted on light microscopy: glomerular basement membrane thickening with little or no cellular proliferation or infiltration [",
"    <a class=\"abstract\" href=\"UTD.htm?18/54/19306/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. MN is most often idiopathic, although it has been associated with hepatitis B antigenemia, autoimmune diseases, thyroiditis, malignancies, and the use of certain drugs such as gold,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/6/4200?source=see_link\">",
"     penicillamine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/59/9145?source=see_link\">",
"     captopril",
"    </a>",
"    , and nonsteroidal antiinflammatory drugs. In the majority of cases of tumor-associated MN, the malignancy has been diagnosed or is clinically apparent at the time that proteinuria is discovered.",
"   </p>",
"   <p>",
"    The pathogenesis, causes, and diagnosis of MN will be reviewed here. The treatment and prognosis of MN are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/41/37530?source=see_link\">",
"     \"Treatment of idiopathic membranous nephropathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/39/12918?source=see_link\">",
"     \"Alternative agents in the treatment of idiopathic membranous nephropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;At one time, membranous nephropathy (MN) was the most common biopsy diagnosis in adults (particularly over age 40 years) with the nephrotic syndrome, but the relative frequency of MN on kidney biopsy has declined to between 15 and 33 percent since 1990 [",
"    <a class=\"abstract\" href=\"UTD.htm?18/54/19306/abstract/3-6\">",
"     3-6",
"    </a>",
"    ]. This reflects at least in part an increase in the relative frequency with which focal segmental glomerulosclerosis is identified in black and Hispanic patients with nephrotic syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?18/54/19306/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/18/32041?source=see_link&amp;anchor=H2#H2\">",
"     \"Overview of heavy proteinuria and the nephrotic syndrome\", section on 'Etiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    MN is seen in all ethnic and racial groups and in both sexes, but idiopathic MN is more common in white males over the age of 40 years. MN in young women should raise the suspicion of lupus. MN is less commonly seen in children, in whom it is often associated with hepatitis B, or less commonly auto-immune or thyroid disease [",
"    <a class=\"abstract\" href=\"UTD.htm?18/54/19306/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The characteristic histologic lesion on light microscopy is diffuse thickening of the glomerular basement membrane (GBM) throughout all glomeruli in the absence of significant hypercellularity (",
"    <a class=\"graphic graphic_picture graphicRef57841 graphicRef74698 graphicRef55226 graphicRef69629 graphicRef62937 graphicRef69348 \" href=\"UTD.htm?0/2/33\">",
"     picture 1A-F",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?18/54/19306/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. However, the glomeruli may appear entirely normal in early cases of MN, and \"spikes\" of GBM extending between the immune deposits may be seen with appropriate stains in more advanced cases. Chronic sclerosing glomerular and tubulointerstitial changes develop as the disease progresses.",
"   </p>",
"   <p>",
"    Immunofluorescence microscopy reveals a diffuse granular pattern of IgG and C3 staining along the GBM. The hallmark lesions on electron microscopy are subepithelial electron dense deposits on the outer aspect of the GBM, effacement of the foot processes of the overlying podocyte, and expansion of the GBM by deposition of new extracellular matrix between the deposits (which are the \"spikes\" seen with special stains).",
"   </p>",
"   <p>",
"    Expansion of the GBM occurs over time as the immune deposits separate from the basal surface of the podocytes and become incorporated into the expanded GBM, as new extracellular matrix is deposited by the injured podocytes. Thus, the disease may be staged according to the extent to which the subepithelial immune deposits are surrounded by the GBM. This staging, though, bears no relationship to the severity of the proteinuria or responsiveness to treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/30/18921?source=see_link\">",
"     \"Mechanisms of immune injury of the glomerulus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These findings are seen in both idiopathic and secondary MN, although there are certain histologic clues to the presence of secondary MN.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Idiopathic versus secondary MN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several histologic characteristics by IF and EM have been identified that may help to distinguish between idiopathic and secondary forms of MN. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Phospholipase A2 receptor'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The presence of tubuloreticular structures in the glomerular endothelial cells (which are induced by alpha-interferon) strongly suggests a diagnosis of membranous lupus nephritis, which may present before the typical systemic and serologic manifestations of the disease. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Systemic lupus erythematosus'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      In idiopathic MN, electron dense deposits on EM are exclusively subepithelial and intramembranous. Secondary forms of MN are often associated with mesangial",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      subendothelial deposits, which suggest a circulating immune complex [",
"      <a class=\"abstract\" href=\"UTD.htm?18/54/19306/abstract/8-10\">",
"       8-10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Tubular basement membrane staining for IgG on immunofluorescence is rare in idiopathic MN, but is common in secondary forms such as SLE. In addition, some patients develop anti-tubular basement membrane antibodies with tubulointerstitial nephritis [",
"      <a class=\"abstract\" href=\"UTD.htm?18/54/19306/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The IgG deposits in idiopathic MN are predominantly IgG4, whereas other isotypes have been described in certain causes of secondary MN. As an example, in lupus-associated MN, IgG1 and IgG3 may predominate, and glomeruli may stain positively for IgA, IgM and C1q as well [",
"      <a class=\"abstract\" href=\"UTD.htm?18/54/19306/abstract/12,13\">",
"       12,13",
"      </a>",
"      ]. In contrast, a predominance of IgG1 and IgG2 has been reported in the putative malignancy-associated MN [",
"      <a class=\"abstract\" href=\"UTD.htm?18/54/19306/abstract/14\">",
"       14",
"      </a>",
"      ]. However, isotype-specific stains are not routinely available.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Even in the absence of an identifiable underlying systemic disease or offending drug, patients with mesangial deposits may have a more favorable long-term prognosis than those with idiopathic MN limited to the subepithelial space [",
"    <a class=\"abstract\" href=\"UTD.htm?18/54/19306/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Animal models",
"    </span>",
"    &nbsp;&mdash;&nbsp;Experimental models of MN suggest that the glomerular basement membrane immune deposits develop in situ with the movement across the GBM of circulating IgG antibodies directed against endogenous antigens expressed on or near the podocyte foot processes, or against circulating cationic or low molecular weight antigens that have crossed the anionic charge barrier in the GBM.",
"   </p>",
"   <p>",
"    The pathogenic mechanisms leading to MN have been primarily elucidated from the rat model of Heymann nephritis, which closely resembles the human disease at both the clinical and histologic level [",
"    <a class=\"abstract\" href=\"UTD.htm?18/54/19306/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. In Heymann nephritis, circulating antibodies target the endocytic receptor megalin (gp330) on podocyte foot processes. The resultant subepithelial immune deposits activate complement, which leads to the assembly of C5b-9, the membrane attack complex, and its insertion into the podocyte plasma membrane [",
"    <a class=\"abstract\" href=\"UTD.htm?18/54/19306/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. Subsequent complement-mediated podocyte injury leads to two changes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Proteinuria via activation of signaling pathways in the podocyte that results in redistribution of actin and loss of slit diaphragm integrity [",
"      <a class=\"abstract\" href=\"UTD.htm?18/54/19306/abstract/17-19\">",
"       17-19",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      GBM expansion by the overproduction of type IV collagen and laminin by the injured podocytes [",
"      <a class=\"abstract\" href=\"UTD.htm?18/54/19306/abstract/20-22\">",
"       20-22",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Megalin is not expressed in the human glomerulus although other antigens have been implicated in human MN, such as the phospholipase A2 receptor and neutral endopeptidase. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Phospholipase A2 receptor'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H8\">",
"     'Neutral endopeptidase'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Phospholipase A2 receptor",
"    </span>",
"    &nbsp;&mdash;&nbsp;The M-type phospholipase A2 receptor (PLA2R), a transmembrane receptor that is highly expressed in glomerular podocytes, has been identified as a major antigen in human idiopathic MN [",
"    <a class=\"abstract\" href=\"UTD.htm?18/54/19306/abstract/23\">",
"     23",
"    </a>",
"    ]. In this study, circulating autoantibodies to PLA2R were identified in 26 of 37 (70 percent) patients with idiopathic MN and could be associated with disease activity in patients for whom serial serum samples were available [",
"    <a class=\"abstract\" href=\"UTD.htm?18/54/19306/abstract/23\">",
"     23",
"    </a>",
"    ]. In contrast, there was no evidence of PLA2R antibodies in serum from eight patients with secondary MN due to lupus or hepatitis B; from 15 patients with proteinuric conditions other than membranous nephropathy (such as diabetic nephropathy or focal segmental glomerulosclerosis); or from 30 healthy control individuals. The circulating anti-PLA2R antibodies were predominantly IgG4, the IgG subclass that is most abundant in the glomerular immune deposits in idiopathic (but not secondary) MN. PLA2R co-localized with IgG4 in immune deposits of kidney tissue obtained by kidney biopsy from patients with MN, and anti-PLA2R antibodies could be eluted from this tissue. This was in contrast to the findings in secondary MN biopsies, in which there was no co-localization of IgG4 and PLA2R, and from which no anti-PLA2R antibodies could be eluted.",
"   </p>",
"   <p>",
"    Anti-PLA2R antibodies have been identified in 57, 74, 78 and 82 percent of patients with idiopathic membranous nephropathy in four additional cohorts from Europe and China [",
"    <a class=\"abstract\" href=\"UTD.htm?18/54/19306/abstract/24-27\">",
"     24-27",
"    </a>",
"    ]. In one study, anti-PLA2R strongly correlated with clinical status [",
"    <a class=\"abstract\" href=\"UTD.htm?18/54/19306/abstract/26\">",
"     26",
"    </a>",
"    ]; in another, lower anti-PLA2R titers were associated with a higher rate of spontaneous remission [",
"    <a class=\"abstract\" href=\"UTD.htm?18/54/19306/abstract/27\">",
"     27",
"    </a>",
"    ]; and in a third study, a decline in anti-PLA2R predicted the clinical response to immunosuppressive therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?18/54/19306/abstract/28\">",
"     28",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/41/37530?source=see_link&amp;anchor=H30#H30\">",
"     \"Treatment of idiopathic membranous nephropathy\", section on 'Resistant disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the study with the relatively low sensitivity of 57 percent, an additional 24 percent of patients, who did not have circulating anti-PLA2R, had the PLA2R antigen within the immune deposits as detected by immunofluorescence of the biopsy specimen, perhaps providing a histopathological clue of recent immunological disease activity [",
"    <a class=\"abstract\" href=\"UTD.htm?18/54/19306/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The detection of anti-PLA2R in the majority of adult patients with idiopathic MN represents a large step forward in our understanding of the disease, as investigators will now be able to test whether the pathogenetic mechanisms learned from experimental models are also involved in human disease. The sensitivity and specificity of anti-PLA2R autoantibodies in individuals with immunologically active idiopathic MN may also allow the development of a serologic immunoassay for the non-invasive diagnosis of idiopathic MN and monitoring of disease activity. It should be noted that, while the association of these anti-PLA2R autoantibodies with disease activity might suggest a causal role, it has not yet been demonstrated that these antibodies cause human MN.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Neutral endopeptidase",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neutral endopeptidase (NEP), which is expressed on podocytes, is the probable target in a rare antenatal form of MN [",
"    <a class=\"abstract\" href=\"UTD.htm?18/54/19306/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. The transplacental passage of anti-NEP antibodies (from mothers genetically deficient in NEP who were alloimmunized during a prior pregnancy) caused MN with subepithelial immune deposits (anti-NEP and NEP) in the",
"    <span class=\"nowrap\">",
"     fetus/neonate.",
"    </span>",
"    Nephrotic syndrome resolved several months after birth, with disappearance of the deposits, upon clearance of the maternal antibodies. Although non-complement-fixing IgG4 was the predominant IgG subclass of anti-NEP in alloimmunized NEP-deficient mothers, the development of proteinuria in their babies correlated with the additional presence of complement-fixing IgG1 anti-NEP [",
"    <a class=\"abstract\" href=\"UTD.htm?18/54/19306/abstract/30\">",
"     30",
"    </a>",
"    ]. This finding, together with reports showing that C5b-9 is shed into the urine of patients with recent onset MN [",
"    <a class=\"abstract\" href=\"UTD.htm?18/54/19306/abstract/31,32\">",
"     31,32",
"    </a>",
"    ], provides additional evidence that the observations in Heymann nephritis are relevant to the human disease. It has yet to be determined however, if the IgG4 anti-PLA2R antibodies that predominate in idiopathic MN or accompanying IgG1 antibodies are responsible for complement activation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5350192\">",
"    <span class=\"h2\">",
"     Intracellular antigens",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to the PLA2R and neutral endopeptidase, antibodies directed against other antigens expressed by podocytes may contribute to the pathogenesis of MN [",
"    <a class=\"abstract\" href=\"UTD.htm?18/54/19306/abstract/33-35\">",
"     33-35",
"    </a>",
"    ]. In one study, for example, serum IgG4 reactivity against aldose reductase, superoxide dismutase 2, and alpha-enolase, as well as the PLA2R and neutral endopeptidase, was measured in 186 patients with MN, 36 patients with focal glomerulosclerosis, and 60 patients with IgA nephropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?18/54/19306/abstract/33\">",
"     33",
"    </a>",
"    ]. Elevated titers of IgG4 against the PLA2R, alpha-enolase, aldose reductase, and superoxide dismutase 2 were found in 60, 43, 34, and 28 percent of patients with MN, respectively, but not in patients with other glomerular diseases. Approximately half of the patients who were negative for antibodies against the PLA2R had an elevated titer for one of the other three antibodies. Although these antigens are predominantly intracellular, it has been proposed that podocyte injury causes the intracellular enzymes to translocate to the cell surface where they are accessible to the circulating antibodies, causing amplification of the immune injury and possibly aggravating the course of the disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H93126072\">",
"    <span class=\"h2\">",
"     Cationic bovine serum albumin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antibodies to a cationic form of bovine serum albumin (BSA) are present in a small number of children with MN [",
"    <a class=\"abstract\" href=\"UTD.htm?18/54/19306/abstract/36\">",
"     36",
"    </a>",
"    ]. The BSA antigen, which was found within the immune deposits of biopsy specimens from these patients, is thought to be absorbed from the relatively underdeveloped pediatric intestinal tract in a partially-digested or undigested form, and then serve as a planted antigen within the glomerular capillary wall. Antibodies reactive with bovine, but not human, serum albumin were eluted from the kidney biopsy specimen in one case.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H93126080\">",
"    <span class=\"h2\">",
"     Other antigens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other antigens have been identified within the glomerular immune deposits in patients with secondary MN [",
"    <a class=\"abstract\" href=\"UTD.htm?18/54/19306/abstract/37\">",
"     37",
"    </a>",
"    ]. These antigens include double stranded DNA in systemic lupus erythematosus, thyroglobulin in thyroiditis, hepatitis B antigen, treponemal antigen and Helicobacter pylori in the relevant infections, and carcinoembryonic antigen and prostate specific antigen in malignancy. The pathogenicity of these antigens is unproven.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Role of T cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;T helper cells activate different immune effector mechanisms and appear to play a role in the pathogenesis of glomerulonephritis and may also participate in the genesis of proteinuria in MN. The T helper subset Th1 tends to predominate in proliferative and crescentic forms of glomerulonephritis, whereas Th2 predominates in MN and minimal change disease [",
"    <a class=\"abstract\" href=\"UTD.htm?18/54/19306/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/58/6056?source=see_link&amp;anchor=H11#H11\">",
"     \"The adaptive cellular immune response\", section on 'Cytokine secretion profiles of activated T cells'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/30/18921?source=see_link&amp;anchor=H10#H10\">",
"     \"Mechanisms of immune injury of the glomerulus\", section on 'T cells'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In support of a pathogenetic role for Th2 in MN is the observation in a model of lupus nephritis that deletion of the WSX-1 gene (encoding a cytokine receptor integral for mounting a Th1 response) causes a shift toward a Th2 response, and converts the diffuse proliferative pattern that is typically seen to a membranous pattern [",
"    <a class=\"abstract\" href=\"UTD.htm?18/54/19306/abstract/40\">",
"     40",
"    </a>",
"    ]. The site of the target antigen and subepithelial location of the immune deposits also favor antibody- and complement-mediated injury to the podocyte, rather than a direct cellular inflammatory lesion (which is typically associated with subendothelial immune deposits and glomerular endothelial injury) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/54/19306/abstract/41,42\">",
"     41,42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most cases of MN in adults are idiopathic (approximately 75 percent). Secondary MN has been attributed to a variety of agents or conditions (",
"    <a class=\"graphic graphic_table graphicRef80418 \" href=\"UTD.htm?14/6/14443\">",
"     table 1",
"    </a>",
"    ), largely due to observations that removal of the inciting agent or treatment of the condition led to resolution of the nephrotic syndrome.",
"   </p>",
"   <p>",
"    Other than by associating a medication or disease state with MN, it is not possible to distinguish idiopathic from secondary MN based solely upon the clinical manifestations. However, there are certain findings on electron microscopy and immunofluorescence that suggest secondary disease. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Idiopathic versus secondary MN'",
"    </a>",
"    above.) In addition, the identification of anti-PLA2R antibodies in idiopathic, but not secondary forms of, MN may allow for future discrimination of these two entities. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Phospholipase A2 receptor'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H61680974\">",
"    <span class=\"h2\">",
"     Genetic associations",
"    </span>",
"    &nbsp;&mdash;&nbsp;A genome-wide association study that included 75 French, 146 Dutch and 335 British individuals identified single-nucleotide polymorphisms (SNPs) at two loci that are highly associated with idiopathic membranous nephropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?18/54/19306/abstract/43\">",
"     43",
"    </a>",
"    ]. The two loci are within the genes for the phospholipase A2 receptor (PLA2R) on chromosome 2q24, and the HLA complex class II alpha chain 1A (HLA-DQA1) on chromosome 6p21. The phospholipase A2 receptor has been identified as a major antigen in idiopathic membranous nephropathy. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Phospholipase A2 receptor'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    When the French, Dutch and British cohorts were analyzed separately the HLA-DQ1 allele was associated with disease in all three populations; the PLA2R allele was associated in the Dutch and British populations, but not in the French. Homozygous expression of the HLA-DQA1 allele conferred a higher risk for disease compared to the PLA2R allele (odds ratios of 20.2 versus 4.2, respectively). The homozygous expression of both alleles additively increased the risk of disease (odds ratio 78.5).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Systemic lupus erythematosus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 10 to 20 percent of patients with lupus nephritis have MN, called class V lupus nephritis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/3/27706?source=see_link\">",
"     \"Diagnosis and classification of renal disease in systemic lupus erythematosus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some patients with membranous lupus present only with renal disease and have no symptoms or serologic abnormalities suggestive of lupus, although such findings may arise several months after presentation with the nephrotic syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?18/54/19306/abstract/8,44\">",
"     8,44",
"    </a>",
"    ]. Lupus should be suspected in any young woman with apparently idiopathic MN. In addition, there are some histologic findings on immunofluorescence (staining for IgA, IgM and C1q) and EM (subendothelial and subepithelial immune deposits and tubuloreticular structures in the glomerular endothelial cells) that are suggestive of underlying lupus [",
"    <a class=\"abstract\" href=\"UTD.htm?18/54/19306/abstract/8,44\">",
"     8,44",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Idiopathic versus secondary MN'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In case reports, membranous lupus has been associated with a concurrent crescentic glomerulonephritis, a relationship that has also been described in idiopathic MN. (See",
"    <a class=\"local\" href=\"#H22\">",
"     'Crescentic glomerulonephritis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Drugs, particularly penicillamine and gold",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exposure to a variety of agents that are primarily used to treat rheumatoid arthritis have been implicated in the development of MN, including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/6/4200?source=see_link\">",
"     penicillamine",
"    </a>",
"    , parenteral gold salts, NSAIDs, bucillamine, and possibly anti-tumor necrosis factor agents (anti-TNF;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"     adalimumab",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/54/19306/abstract/45-49\">",
"     45-49",
"    </a>",
"    ]. The incidence of MN may be as high as 7 percent in patients treated with penicillamine, and 1 to 3 percent in those treated with parenteral gold (the risk with oral gold [",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/47/31476?source=see_link\">",
"     auranofin",
"    </a>",
"    ] appears to be lower) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/54/19306/abstract/50-52\">",
"     50-52",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/32/18954?source=see_link&amp;anchor=H37#H37\">",
"     \"Overview of the systemic and nonarticular manifestations of rheumatoid arthritis\", section on 'Kidney disease'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/0/24582?source=see_link\">",
"     \"NSAIDs: Acute kidney injury (acute renal failure) and nephrotic syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/19/3384?source=see_link\">",
"     \"Overview of biologic agents in the rheumatic diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/12/21699?source=see_link\">",
"     Tiopronin",
"    </a>",
"    (2-mercaptopropionylglycine, Thiola), an agent structurally similar to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/6/4200?source=see_link\">",
"     penicillamine",
"    </a>",
"    that is used to treat cystine stones, has also been reported to cause MN, but the incidence is rare [",
"    <a class=\"abstract\" href=\"UTD.htm?18/54/19306/abstract/53\">",
"     53",
"    </a>",
"    ]. High dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/59/9145?source=see_link\">",
"     captopril",
"    </a>",
"    , which also has a free thiol group, has also been associated with MN. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/62/25577?source=see_link\">",
"     \"Cystine stones\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The mechanisms responsible for drug-induced MN are uncertain. Human and experimental data suggest that induction of gold-specific and autoreactive T cells may lead to polyclonal B cell activation and autoantibody production in gold-induced MN [",
"    <a class=\"abstract\" href=\"UTD.htm?18/54/19306/abstract/54,55\">",
"     54,55",
"    </a>",
"    ]. Interestingly, it has been suggested that patients carrying the lupus-associated HLA alleles DRB1*0301 (DR3) and DQA1*0501 are particularly susceptible to develop MN, as well as drug-induced lupus, after exposure to gold salts [",
"    <a class=\"abstract\" href=\"UTD.htm?18/54/19306/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Proteinuria generally develops within the first 6 to 12 months of drug therapy, but can occur as late as three to four years [",
"    <a class=\"abstract\" href=\"UTD.htm?18/54/19306/abstract/52\">",
"     52",
"    </a>",
"    ]. Discontinuation of the drug leads to resolution of the proteinuria in virtually all cases [",
"    <a class=\"abstract\" href=\"UTD.htm?18/54/19306/abstract/50,52\">",
"     50,52",
"    </a>",
"    ]. However, studies with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/6/4200?source=see_link\">",
"     penicillamine",
"    </a>",
"    , gold, and bucillamine indicate that protein excretion may continue to rise for the first 1 to 12 months (two months on average) after the cessation of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?18/54/19306/abstract/52\">",
"     52",
"    </a>",
"    ]. The mean time to resolution of the proteinuria is 9 to 12 months, although two to three years is required in some cases [",
"    <a class=\"abstract\" href=\"UTD.htm?18/54/19306/abstract/46,50,52\">",
"     46,50,52",
"    </a>",
"    ]. The prolonged time to recovery may be related in part to the slow rate of clearance of subepithelial immune deposits and to slow remodeling of the disorganized GBM [",
"    <a class=\"abstract\" href=\"UTD.htm?18/54/19306/abstract/21,41\">",
"     21,41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It should be noted that MN is not the only glomerulopathy seen with these drugs. Gold and NSAID can lead to minimal change disease [",
"    <a class=\"abstract\" href=\"UTD.htm?18/54/19306/abstract/52\">",
"     52",
"    </a>",
"    ], whereas",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/6/4200?source=see_link\">",
"     penicillamine",
"    </a>",
"    can induce an immune complex crescentic glomerulonephritis. Anti-TNF therapy has also been associated with the new onset of lupus nephritis and pauci-immune necrotizing and crescentic GN [",
"    <a class=\"abstract\" href=\"UTD.htm?18/54/19306/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Nonsteroidal antiinflammatory drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although initial reports found that most cases of NSAID-induced nephrotic syndrome that were biopsied had minimal change disease, it is now evident that MN can also occur [",
"    <a class=\"abstract\" href=\"UTD.htm?18/54/19306/abstract/57,58\">",
"     57,58",
"    </a>",
"    ]. The association of NSAIDs with MN was illustrated in a study of 125 patients with a biopsy diagnosis of MN [",
"    <a class=\"abstract\" href=\"UTD.htm?18/54/19306/abstract/57\">",
"     57",
"    </a>",
"    ]. Twenty-nine patients were taking an NSAID and 13 (10 percent of the study population) fulfilled three criteria suggesting that the NSAID was responsible:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      No other apparent cause for the MN",
"     </li>",
"     <li>",
"      Resolution of proteinuria within 1 to 36 weeks of discontinuing NSAIDs",
"     </li>",
"     <li>",
"      No recurrence of proteinuria at follow-up (5 months to 13 years)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Many of the patients who developed MN had been treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/29/38352?source=see_link\">",
"     diclofenac",
"    </a>",
"    , but probably any NSAID can be involved [",
"    <a class=\"abstract\" href=\"UTD.htm?18/54/19306/abstract/57\">",
"     57",
"    </a>",
"    ], including COX-2 inhibitors [",
"    <a class=\"abstract\" href=\"UTD.htm?18/54/19306/abstract/59\">",
"     59",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/0/24582?source=see_link\">",
"     \"NSAIDs: Acute kidney injury (acute renal failure) and nephrotic syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Hepatitis B virus",
"    </span>",
"    &nbsp;&mdash;&nbsp;MN due to hepatitis B virus infection primarily occurs in children in endemic areas, many of whom are asymptomatic carriers with no history of active hepatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/54/19306/abstract/7,60-63\">",
"     7,60-63",
"    </a>",
"    ]. The serum transaminases tend to be normal or only mildly elevated, and the serology is positive for surface antigen, anti-core antibody, and usually e antigen. It appears that it is the e antigen and cationic anti-e antibody that are primarily deposited in the glomeruli [",
"    <a class=\"abstract\" href=\"UTD.htm?18/54/19306/abstract/7,8,60\">",
"     7,8,60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hepatitis B virus infection represents, with lupus, the only form of MN that may be associated with hypocomplementemia [",
"    <a class=\"abstract\" href=\"UTD.htm?18/54/19306/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Spontaneous resolution of the proteinuria is common in children with MN associated with hepatitis B virus infection, but not in adults, many of whom will have progressive disease [",
"    <a class=\"abstract\" href=\"UTD.htm?18/54/19306/abstract/60\">",
"     60",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/28/44488?source=see_link\">",
"     \"Renal disease associated with hepatitis B virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Hepatitis C virus",
"    </span>",
"    &nbsp;&mdash;&nbsp;MN may also be associated with chronic HCV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?18/54/19306/abstract/64\">",
"     64",
"    </a>",
"    ]. This is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/30/37353?source=see_link\">",
"     \"Renal disease associated with hepatitis C virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Malignancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Up to 5 to 20 percent of adults with MN, particularly those over the age of 65 years, have been reported to have a malignancy, most commonly a solid tumor (principally carcinoma of the prostate, lung, or gastrointestinal track), and less frequently, a hematologic malignancy, such as chronic lymphocytic leukemia [",
"    <a class=\"abstract\" href=\"UTD.htm?18/54/19306/abstract/65-72\">",
"     65-72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Based upon the population examined, the risk of malignancy among those with MN can vary from 2 to 12 times higher than that observed in the general population after adjustment for age and gender [",
"    <a class=\"abstract\" href=\"UTD.htm?18/54/19306/abstract/71,72\">",
"     71,72",
"    </a>",
"    ]. The malignancy has been presumed to be etiologically associated when removal of the tumor was followed by gradual remission of the proteinuria.",
"   </p>",
"   <p>",
"    A proposed mechanism is that deposition of tumor antigens in the glomeruli promotes antibody deposition and complement activation, leading to epithelial cell and GBM injury, and consequent proteinuria [",
"    <a class=\"abstract\" href=\"UTD.htm?18/54/19306/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A direct causal relationship, rather than coincident disease, has been questioned for the following reasons:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The putatively associated tumors are common in males over the age of 50 years, the same population that tends to get MN.",
"     </li>",
"     <li>",
"      Remission of the nephrotic syndrome with removal of the tumor does not necessarily imply a therapeutic response, since there is a relatively high rate of spontaneous remission in MN (",
"      <a class=\"graphic graphic_figure graphicRef61059 \" href=\"UTD.htm?30/50/31533\">",
"       figure 1",
"      </a>",
"      ), and relapse of MN with tumor recurrence would be expected (but is not well described).",
"     </li>",
"     <li>",
"      Relative to the high incidence of malignancy in patients with MN, detection of tumor antigens in the GBM is only rarely described [",
"      <a class=\"abstract\" href=\"UTD.htm?18/54/19306/abstract/73-76\">",
"       73-76",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Regardless of whether the malignancy is a causal factor or simply coincident, in many cases it has already been diagnosed or is clinically apparent at the onset of proteinuria [",
"    <a class=\"abstract\" href=\"UTD.htm?18/54/19306/abstract/71\">",
"     71",
"    </a>",
"    ]. A diagnosis of MN preceding that of malignancy is more likely in older adults [",
"    <a class=\"abstract\" href=\"UTD.htm?18/54/19306/abstract/65,71\">",
"     65,71",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H25\">",
"     'Screening for malignancy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4189223\">",
"    <span class=\"h2\">",
"     Syphilis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Congenital and secondary syphilis have been associated with MN [",
"    <a class=\"abstract\" href=\"UTD.htm?18/54/19306/abstract/70,77-81\">",
"     70,77-81",
"    </a>",
"    ]. Treponemal antigens have been identified in the glomeruli by immunofluorescence microscopy and eluates from glomerular deposits contain antibodies specific for Treponema pallidum antigen [",
"    <a class=\"abstract\" href=\"UTD.htm?18/54/19306/abstract/77,78,80\">",
"     77,78,80",
"    </a>",
"    ]. Furthermore, effective treatment of syphilis can lead to resolution of the glomerular disease [",
"    <a class=\"abstract\" href=\"UTD.htm?18/54/19306/abstract/77,79-81\">",
"     77,79-81",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/9/37017?source=see_link&amp;anchor=H26#H26\">",
"     \"Pathogenesis, clinical manifestations, and treatment of early syphilis\", section on 'Therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4662280\">",
"    <span class=\"h2\">",
"     IgG4-related disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunoglobulin G4 (IgG4)-related disease is an increasingly recognized systemic syndrome of unknown etiology characterized by tumor-like swelling of involved organs, a lymphoplasmacytic infiltrate enriched in IgG4-positive plasma cells, and variable degrees of fibrosis that has a characteristic \"storiform\" pattern. In addition, elevated serum concentrations of IgG4 are found in 60 to 70 percent of patients with IgG4-related disease. The major renal manifestation associated with IgG4-related disease is tubulointerstitial nephritis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/55/13178?source=see_link&amp;anchor=H16601972#H16601972\">",
"     \"Overview of IgG4-related disease\", section on 'Tubulointerstitial nephritis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, IgG4-related disease may also be associated with membranous nephropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?18/54/19306/abstract/82-85\">",
"     82-85",
"    </a>",
"    ]. This was described in nine patients with membranous nephropathy who also had other manifestations of IgG4-related disease (mostly pancreatitis, tubulointerstitial nephritis, or sialoadenitis) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/54/19306/abstract/82\">",
"     82",
"    </a>",
"    ]. Antibodies against the PLA2R, commonly present in patients with primary membranous nephropathy, were",
"    <strong>",
"     absent",
"    </strong>",
"    in all patients. In addition, none of the nine patients had evidence for systemic lupus erythematosus, hepatitis virus infection, or cancer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Hematopoietic cell transplantation and graft-versus-host-disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nephrotic syndrome occasionally arises in recipients of autologous stem cell or, less commonly, bone marrow transplants, and is often temporally correlated with chronic GVHD.",
"   </p>",
"   <p>",
"    MN is the most frequently reported underlying histology, although minimal change disease is also seen. The occurrence of MN is often associated with a decrease in immunosuppression. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/36/1609?source=see_link&amp;anchor=H12#H12\">",
"     \"Kidney disease following hematopoietic cell transplantation\", section on 'Nephrotic syndrome'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/25/23962?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and grading of chronic graft-versus-host disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Kidney transplant",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although MN occasionally recurs after renal transplantation, de novo MN is more common in transplant recipients. Alloimmunization against minor histocompatibility antigens or privately expressed donor epitopes may play a role [",
"    <a class=\"abstract\" href=\"UTD.htm?18/54/19306/abstract/37\">",
"     37",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/18/34088?source=see_link\">",
"     \"Membranous nephropathy and renal transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Others",
"    </span>",
"    &nbsp;&mdash;&nbsp;MN has been infrequently reported in association with a variety of other conditions in case reports or small series (",
"    <a class=\"graphic graphic_table graphicRef80418 \" href=\"UTD.htm?14/6/14443\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/54/19306/abstract/2,70,86\">",
"     2,70,86",
"    </a>",
"    ]. These include hepatosplenic schistosomiasis, quartan malaria, sarcoidosis, Sj&ouml;gren's syndrome, and chronic exposure to formaldehyde [",
"    <a class=\"abstract\" href=\"UTD.htm?18/54/19306/abstract/63,70,87\">",
"     63,70,87",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/28/34243?source=see_link\">",
"     \"Schistosomiasis and glomerular disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/31/40438?source=see_link\">",
"     \"Renal disease in sarcoidosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/12/20677?source=see_link\">",
"     \"Renal disease in Sj&ouml;gren's syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     MEMBRANOUS NEPHROPATHY WITH OTHER GLOMERULAR DISEASES",
"    </span>",
"    &nbsp;&mdash;&nbsp;MN may be seen in conjunction with other glomerular diseases. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Diabetic nephropathy (see",
"      <a class=\"local\" href=\"#H21\">",
"       'Diabetes mellitus'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Crescentic (rapidly progressive) glomerulonephritis (see",
"      <a class=\"local\" href=\"#H22\">",
"       'Crescentic glomerulonephritis'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Focal segmental glomerulosclerosis (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/6/41066?source=see_link\">",
"       \"Epidemiology, classification, and pathogenesis of focal segmental glomerulosclerosis\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      IgA nephropathy (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/19/1337?source=see_link&amp;anchor=H9#H9\">",
"       \"Clinical presentation and diagnosis of IgA nephropathy\", section on 'Minimal change disease and membranous nephropathy'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is unclear if these disorders are causally related to MN or have developed concurrently. In addition, the mechanism may vary with the second disease. With focal segmental glomerulosclerosis, for example, the sclerotic lesions may reflect a response to injury induced by the membranous disease",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    secondary intraglomerular hypertension, rather than a separate disorder. Patients with these sclerotic lesions have a much higher likelihood of progressive renal insufficiency than those with uncomplicated MN [",
"    <a class=\"abstract\" href=\"UTD.htm?18/54/19306/abstract/88,89\">",
"     88,89",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/6/41066?source=see_link&amp;anchor=H13#H13\">",
"     \"Epidemiology, classification, and pathogenesis of focal segmental glomerulosclerosis\", section on 'Secondary FSGS'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Diabetes mellitus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Membranous nephropathy (as well as other glomerular diseases) can occur in patients with diabetes with or without diabetic nephropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?18/54/19306/abstract/90,91\">",
"     90,91",
"    </a>",
"    ]. In most cases, the diseases are not related but porcine insulin may be the inciting antigen in some patients.",
"   </p>",
"   <p>",
"    A possible pathogenetic role for porcine insulin was suggested in a report of seven patients with diabetes who developed MN [",
"    <a class=\"abstract\" href=\"UTD.htm?18/54/19306/abstract/91\">",
"     91",
"    </a>",
"    ]. Three of the patients had granular deposits of porcine insulin, as detected by anti-porcine insulin antibodies, as well as IgG and complement along the glomerular capillary wall. The nephrotic syndrome developed after the initiation of porcine insulin in all three patients and, in two of these patients, switching from porcine to human insulin led to amelioration of the proteinuria. The other four patients were thought to have idiopathic MN.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Crescentic glomerulonephritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;MN is infrequently associated with a crescentic glomerulonephritis that may be related to antineutrophil cytoplasmic antibodies (ANCA) or, less often, anti-glomerular basement membrane (GBM) antibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?18/54/19306/abstract/92-97\">",
"     92-97",
"    </a>",
"    ]. This relationship has mostly been described in patients with idiopathic MN, but there are also case reports in patients with membranous lupus [",
"    <a class=\"abstract\" href=\"UTD.htm?18/54/19306/abstract/98\">",
"     98",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Systemic lupus erythematosus'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Crescentic glomerulonephritis and the associated nephritic sediment can be superimposed upon preexisting MN or occur in conjunction with MN. In a report of 10 patients, for example, nine had concurrent disease at presentation and one developed crescentic glomerulonephritis five years after the original presentation of MN [",
"    <a class=\"abstract\" href=\"UTD.htm?18/54/19306/abstract/92\">",
"     92",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Why these disorders are associated with MN is not clear. One possibility is the coincident production of ANCA or anti-GBM antibodies and the antibody responsible for MN in an individual predisposed to autoimmune disorders. An alternative mechanism is that glomerular basement membrane injury induced by the membranous lesion may expose previously \"unseen\" antigens, leading to anti-GBM antibody production.",
"   </p>",
"   <p>",
"    A study from a major renal pathology laboratory identified 14 patients with both MN and ANCA-associated necrotizing and crescentic glomerulonephritis; both conditions were diagnosed simultaneously in most of these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?18/54/19306/abstract/96\">",
"     96",
"    </a>",
"    ]. In a review of over 13,000 native kidney biopsies processed by the same laboratory, idiopathic MN was present in 8.8 percent and ANCA-associated necrotizing and crescentic glomerulonephritis was present in 3.4 percent. Based upon these numbers, concurrent disease would have been expected",
"    <strong>",
"     by chance",
"    </strong>",
"    in 39 patients, well above the observed 14 cases. It was therefore concluded that concurrent disease represented a chance occurrence of two unrelated disease processes.",
"   </p>",
"   <p>",
"    The findings were different in a retrospective review of 218 patients with MN; 10 (4.6 percent) had crescentic glomerulonephritis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/54/19306/abstract/92\">",
"     92",
"    </a>",
"    ]. The incidence was much higher than would be expected for the random co-occurrence of the two disorders. ANCA were present in four of the nine patients who were tested. In one such case, the patient tested positive for both ANCA and anti-PLA2R [",
"    <a class=\"abstract\" href=\"UTD.htm?18/54/19306/abstract/99\">",
"     99",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with MN (approximately 80 percent) present with the nephrotic syndrome; the remainder are diagnosed following an evaluation for asymptomatic proteinuria. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/18/32041?source=see_link\">",
"     \"Overview of heavy proteinuria and the nephrotic syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because the underlying pathology is due to the gradual accumulation of subepithelial deposits and resultant podocyte damage, the features of the nephrotic syndrome, especially weight gain and lower extremity edema, develop at a slower pace than that observed in patients with minimal change disease or primary focal segmental glomerulosclerosis; thus, the precise onset of disease is less likely to be noticed by the patient or clinician. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Pathology'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/50/34601?source=see_link\">",
"     \"Etiology, clinical features, and diagnosis of minimal change disease in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The amount of proteinuria is variable, ranging from subnephrotic to more than 20",
"    <span class=\"nowrap\">",
"     g/day.",
"    </span>",
"    Proteinuria is typically present for several months prior to the diagnosis of MN by renal biopsy, which highlights the more gradual development of this disease process. Other common abnormalities on urinalysis and urine microscopy include oval fat bodies, lipid droplets, and fatty casts. Microscopic hematuria occurs in up to 50 percent, but red blood cell casts are rare [",
"    <a class=\"abstract\" href=\"UTD.htm?18/54/19306/abstract/2\">",
"     2",
"    </a>",
"    ]. Glucosuria in the presence of normal blood glucose levels is common in patients with nephrotic syndrome, probably a consequence of tubular dysfunction from the heavy albuminuria.",
"   </p>",
"   <p>",
"    Hypoalbuminemia and severe hyperlipidemia are almost always present at diagnosis in patients with the nephrotic syndrome, but usually not in patients with subnephrotic proteinuria. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/41/33430?source=see_link\">",
"     \"Lipid abnormalities in nephrotic syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Approximately 70 percent of patients have normal blood pressure and glomerular filtration rate (GFR) at presentation. Acute renal failure (ARF) is uncommon, and may be due to hypovolemia due to aggressive diuresis, acute interstitial nephritis due to diuretics or other offending drugs, superimposed crescentic glomerulonephritis (which is associated with an active sediment) or rarely from acute renal vein thrombosis leading to renal infarction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/10/18598?source=see_link\">",
"     \"Acute kidney injury (acute renal failure) in minimal change disease and other forms of nephrotic syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/36/27209?source=see_link&amp;anchor=H3#H3\">",
"     \"Clinical manifestations and diagnosis of acute interstitial nephritis\", section on 'Drugs'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/12/3273?source=see_link\">",
"     \"Renal vein thrombosis and hypercoagulable state in nephrotic syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The usual course of patients with MN is either spontaneous or treatment-induced complete or partial remission or persistent nephrotic syndrome with or without slow progression to end-stage renal disease (",
"    <a class=\"graphic graphic_figure graphicRef61059 \" href=\"UTD.htm?30/50/31533\">",
"     figure 1",
"    </a>",
"    ). The prognosis of membranous nephropathy is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/41/37530?source=see_link&amp;anchor=H32#H32\">",
"     \"Treatment of idiopathic membranous nephropathy\", section on 'Prognosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with subnephrotic proteinuria have a benign long-term prognosis as long they remain subnephrotic (less than 3.5 to 4.0",
"    <span class=\"nowrap\">",
"     g/day).",
"    </span>",
"    However, these patients require long-term monitoring of protein excretion since many progress to nephrotic range proteinuria with its associated higher rate of progressive disease. The rationale for prolonged monitoring was provided by a review of 395 patients with MN, 108 of whom (27 percent) presented with subnephrotic proteinuria (less than 3.5",
"    <span class=\"nowrap\">",
"     g/day)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?18/54/19306/abstract/100\">",
"     100",
"    </a>",
"    ]. Among these patients, 66 (61 percent) progressed to nephrotic syndrome, 20 after the first year including 9 after more than four years. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/41/37530?source=see_link&amp;anchor=H18#H18\">",
"     \"Treatment of idiopathic membranous nephropathy\", section on 'Low risk for progression'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of MN can only be made by kidney biopsy, and we suggest obtaining a kidney biopsy in all patients with unexplained nephrotic syndrome (",
"    <a class=\"graphic graphic_picture graphicRef57841 graphicRef74698 graphicRef55226 graphicRef69629 graphicRef62937 graphicRef69348 \" href=\"UTD.htm?0/2/33\">",
"     picture 1A-F",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Pathology'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    There are a number of laboratory tests generally ordered for patients with heavy proteinuria. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/31/27130?source=see_link&amp;anchor=H460668475#H460668475\">",
"     \"Differential diagnosis and evaluation of glomerular disease\", section on 'Patients with a nephrotic presentation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients found to have MN on kidney biopsy, we recommend obtaining the following tests in order to identify a possible secondary cause (see",
"    <a class=\"local\" href=\"#H10\">",
"     'Etiology'",
"    </a>",
"    above):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Antinuclear antibody &mdash; A high titer positive result would suggest membranous lupus nephritis, particularly if associated with hypocomplementemia",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      tubuloreticular structures in the glomerular endothelial cells [",
"      <a class=\"abstract\" href=\"UTD.htm?18/54/19306/abstract/8,44\">",
"       8,44",
"      </a>",
"      ]. A positive test should be confirmed with an anti-double stranded DNA assay. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/16/3338?source=see_link\">",
"       \"Diagnosis and differential diagnosis of systemic lupus erythematosus in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Serum C3 &mdash; Serum complement levels are normal in idiopathic MN, but may be low in MN associated with lupus or hepatitis B.",
"     </li>",
"     <li>",
"      Hepatitis B and C serologies",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Screening for malignancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients with MN will have an underlying malignancy although there is uncertainty regarding causality. In most patients, the malignancy has already been diagnosed or is clinically apparent at the onset of proteinuria. Rarely, the diagnosis of MN precedes that of the malignancy [",
"    <a class=\"abstract\" href=\"UTD.htm?18/54/19306/abstract/65\">",
"     65",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Malignancy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The diagnosis of MN should",
"    <strong>",
"     not",
"    </strong>",
"    prompt an extensive search for occult malignancy in the absence of some suggestive finding such as guaiac positive stools or unexplained anemia or weight loss, unless routine age-appropriate screening has not been previously performed.",
"   </p>",
"   <p>",
"    Our evaluation encompasses routine screening if necessary, including testing the stool for blood, colonoscopy in patients over 50 years of age (or if indicated for other reasons), mammogram in women over 40 years of age, prostate specific antigen in men over the age of 50 years, and, in patients at high risk for lung cancer, chest x-ray and possibly chest computed tomography.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Membranous nephropathy (MN) is among the most common causes of the nephrotic syndrome in nondiabetic adults, accounting for up to one-third of biopsy diagnoses. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/18/32041?source=see_link&amp;anchor=H2#H2\">",
"       \"Overview of heavy proteinuria and the nephrotic syndrome\", section on 'Etiology'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      MN is characterized pathologically by diffuse thickening of the glomerular basement membrane (GBM) on light microscopy, \"spikes\" on silver stain, diffuse granular IgG and complement deposition on immunofluorescence, and subepithelial dense deposits on electron microscopy (",
"      <a class=\"graphic graphic_picture graphicRef57841 graphicRef74698 graphicRef55226 graphicRef69629 graphicRef62937 graphicRef69348 \" href=\"UTD.htm?0/2/33\">",
"       picture 1A-F",
"      </a>",
"      ). Mesangial",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      subendothelial deposits may also be seen with secondary forms of MN, which suggest an associated immune complex disease. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Pathology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Idiopathic versus secondary MN'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The immune deposits that are characteristic of this disorder may develop in situ with the movement across the GBM of circulating IgG antibodies directed against endogenous antigens expressed on or near the podocyte foot processes or against circulating cationic or low molecular weight antigens that have crossed the anionic charge barrier in the GBM. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Antibodies to the M type phospholipase A2 receptor, a major antigen expressed on podocytes, are specifically found in a high proportion of patients with idiopathic MN. Neutral endopeptidase is an antigen in an antenatal form of MN, and antibodies to cationic bovine serum albumin may be found in some children with MN. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      MN is most often idiopathic, although it has been associated with a variety of conditions, including hepatitis B antigenemia, autoimmune diseases (eg, lupus), malignancy and the use of certain drugs such as gold,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/6/4200?source=see_link\">",
"       penicillamine",
"      </a>",
"      , and nonsteroidal antiinflammatory drugs (NSAIDs). MN may also be seen in conjunction with other glomerular diseases such as diabetic nephropathy and crescentic glomerulonephritis. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Etiology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H20\">",
"       'Membranous nephropathy with other glomerular diseases'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most patients with MN present with the nephrotic syndrome, but some have only asymptomatic proteinuria. The serum creatinine is generally normal or near normal on initial presentation. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of MN can only be established by renal biopsy. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      To evaluate for potential secondary forms of MN, we suggest obtaining blood for antinuclear antibodies, serum complement, and hepatitis B and C serology.",
"     </li>",
"     <li>",
"      Screening for malignancy is reasonable if the patient's age warrants routine screening and it has not already been done, or if there is some suggestive finding such as guaiac positive stools or unexplained anemia or weight loss. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Screening for malignancy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19306/abstract/1\">",
"      Austin, HA 3d, Antonovych, TT, MacKay, K, et al. NIH Conference. Membranous nephropathy. Ann Intern Med 1992; 116:672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19306/abstract/2\">",
"      Wasserstein AG. Membranous glomerulonephritis. J Am Soc Nephrol 1997; 8:664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19306/abstract/3\">",
"      Haas M, Meehan SM, Karrison TG, Spargo BH. Changing etiologies of unexplained adult nephrotic syndrome: a comparison of renal biopsy findings from 1976-1979 and 1995-1997. Am J Kidney Dis 1997; 30:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19306/abstract/4\">",
"      Braden GL, Mulhern JG, O'Shea MH, et al. Changing incidence of glomerular diseases in adults. Am J Kidney Dis 2000; 35:878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19306/abstract/5\">",
"      Korbet SM, Genchi RM, Borok RZ, Schwartz MM. The racial prevalence of glomerular lesions in nephrotic adults. Am J Kidney Dis 1996; 27:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19306/abstract/6\">",
"      Rivera F, L&oacute;pez-G&oacute;mez JM, P&eacute;rez-Garc&iacute;a R, Spanish Registry of Glomerulonephritis. Clinicopathologic correlations of renal pathology in Spain. Kidney Int 2004; 66:898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19306/abstract/7\">",
"      Johnson RJ, Couser WG. Hepatitis B infection and renal disease: clinical, immunopathogenetic and therapeutic considerations. Kidney Int 1990; 37:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19306/abstract/8\">",
"      Jennette JC, Iskandar SS, Dalldorf FG. Pathologic differentiation between lupus and nonlupus membranous glomerulopathy. Kidney Int 1983; 24:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19306/abstract/9\">",
"      Takekoshi Y, Tochimaru H, Nagata Y, Itami N. Immunopathogenetic mechanisms of hepatitis B virus-related glomerulopathy. Kidney Int Suppl 1991; 35:S34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19306/abstract/10\">",
"      Davenport A, Maciver AG, Hall CL, MacKenzie JC. Do mesangial immune complex deposits affect the renal prognosis in membranous glomerulonephritis? Clin Nephrol 1994; 41:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19306/abstract/11\">",
"      Katz A, Fish AJ, Santamaria P, et al. Role of antibodies to tubulointerstitial nephritis antigen in human anti-tubular basement membrane nephritis associated with membranous nephropathy. Am J Med 1992; 93:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19306/abstract/12\">",
"      Haas M. IgG subclass deposits in glomeruli of lupus and nonlupus membranous nephropathies. Am J Kidney Dis 1994; 23:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19306/abstract/13\">",
"      Kuroki A, Shibata T, Honda H, et al. Glomerular and serum IgG subclasses in diffuse proliferative lupus nephritis, membranous lupus nephritis, and idiopathic membranous nephropathy. Intern Med 2002; 41:936.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19306/abstract/14\">",
"      Ohtani H, Wakui H, Komatsuda A, et al. Distribution of glomerular IgG subclass deposits in malignancy-associated membranous nephropathy. Nephrol Dial Transplant 2004; 19:574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19306/abstract/15\">",
"      Quigg RJ. Why study membranous nephropathy in rats? Kidney Int 2003; 64:2318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19306/abstract/16\">",
"      Farquhar MG, Saito A, Kerjaschki D, Orlando RA. The Heymann nephritis antigenic complex: megalin (gp330) and RAP. J Am Soc Nephrol 1995; 6:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19306/abstract/17\">",
"      Cybulsky AV, Quigg RJ, Salant DJ. Experimental membranous nephropathy redux. Am J Physiol Renal Physiol 2005; 289:F660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19306/abstract/18\">",
"      Nangaku M, Shankland SJ, Couser WG. Cellular response to injury in membranous nephropathy. J Am Soc Nephrol 2005; 16:1195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19306/abstract/19\">",
"      Cunningham PN, Quigg RJ. Contrasting roles of complement activation and its regulation in membranous nephropathy. J Am Soc Nephrol 2005; 16:1214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19306/abstract/20\">",
"      Floege J, Johnson RJ, Gordon K, et al. Altered glomerular extracellular matrix synthesis in experimental membranous nephropathy. Kidney Int 1992; 42:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19306/abstract/21\">",
"      Minto AW, Kalluri R, Togawa M, et al. Augmented expression of glomerular basement membrane specific type IV collagen isoforms (alpha3-alpha5) in experimental membranous nephropathy. Proc Assoc Am Physicians 1998; 110:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19306/abstract/22\">",
"      Kim Y, Butkowski R, Burke B, et al. Differential expression of basement membrane collagen in membranous nephropathy. Am J Pathol 1991; 139:1381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19306/abstract/23\">",
"      Beck LH Jr, Bonegio RG, Lambeau G, et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med 2009; 361:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19306/abstract/24\">",
"      Debiec H, Ronco P. PLA2R autoantibodies and PLA2R glomerular deposits in membranous nephropathy. N Engl J Med 2011; 364:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19306/abstract/25\">",
"      Qin W, Beck LH Jr, Zeng C, et al. Anti-phospholipase A2 receptor antibody in membranous nephropathy. J Am Soc Nephrol 2011; 22:1137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19306/abstract/26\">",
"      Hofstra JM, Beck LH Jr, Beck DM, et al. Anti-phospholipase A receptor antibodies correlate with clinical status in idiopathic membranous nephropathy. Clin J Am Soc Nephrol 2011; 6:1286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19306/abstract/27\">",
"      Hofstra JM, Debiec H, Short CD, et al. Antiphospholipase A2 receptor antibody titer and subclass in idiopathic membranous nephropathy. J Am Soc Nephrol 2012; 23:1735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19306/abstract/28\">",
"      Beck LH Jr, Fervenza FC, Beck DM, et al. Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy. J Am Soc Nephrol 2011; 22:1543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19306/abstract/29\">",
"      Debiec H, Guigonis V, Mougenot B, et al. Antenatal membranous glomerulonephritis due to anti-neutral endopeptidase antibodies. N Engl J Med 2002; 346:2053.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19306/abstract/30\">",
"      Debiec H, Nauta J, Coulet F, et al. Role of truncating mutations in MME gene in fetomaternal alloimmunisation and antenatal glomerulopathies. Lancet 2004; 364:1252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19306/abstract/31\">",
"      Schulze M, Donadio JV Jr, Pruchno CJ, et al. Elevated urinary excretion of the C5b-9 complex in membranous nephropathy. Kidney Int 1991; 40:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19306/abstract/32\">",
"      Kon SP, Coupes B, Short CD, et al. Urinary C5b-9 excretion and clinical course in idiopathic human membranous nephropathy. Kidney Int 1995; 48:1953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19306/abstract/33\">",
"      Murtas C, Bruschi M, Candiano G, et al. Coexistence of different circulating anti-podocyte antibodies in membranous nephropathy. Clin J Am Soc Nephrol 2012; 7:1394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19306/abstract/34\">",
"      Bruschi M, Carnevali ML, Murtas C, et al. Direct characterization of target podocyte antigens and auto-antibodies in human membranous glomerulonephritis: Alfa-enolase and borderline antigens. J Proteomics 2011; 74:2008.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19306/abstract/35\">",
"      Prunotto M, Carnevali ML, Candiano G, et al. Autoimmunity in membranous nephropathy targets aldose reductase and SOD2. J Am Soc Nephrol 2010; 21:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19306/abstract/36\">",
"      Debiec H, Lefeu F, Kemper MJ, et al. Early-childhood membranous nephropathy due to cationic bovine serum albumin. N Engl J Med 2011; 364:2101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19306/abstract/37\">",
"      Ronco P, Debiec H. Molecular pathomechanisms of membranous nephropathy: from Heymann nephritis to alloimmunization. J Am Soc Nephrol 2005; 16:1205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19306/abstract/38\">",
"      Tipping PG, Kitching AR. Glomerulonephritis, Th1 and Th2: what's new? Clin Exp Immunol 2005; 142:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19306/abstract/39\">",
"      Kuroki A, Iyoda M, Shibata T, Sugisaki T. Th2 cytokines increase and stimulate B cells to produce IgG4 in idiopathic membranous nephropathy. Kidney Int 2005; 68:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19306/abstract/40\">",
"      Shimizu S, Sugiyama N, Masutani K, et al. Membranous glomerulonephritis development with Th2-type immune deviations in MRL/lpr mice deficient for IL-27 receptor (WSX-1). J Immunol 2005; 175:7185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19306/abstract/41\">",
"      Fries JW, Mendrick DL, Rennke HG. Determinants of immune complex-mediated glomerulonephritis. Kidney Int 1988; 34:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19306/abstract/42\">",
"      Salant DJ, Adler S, Darby C, et al. Influence of antigen distribution on the mediation of immunological glomerular injury. Kidney Int 1985; 27:938.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19306/abstract/43\">",
"      Stanescu HC, Arcos-Burgos M, Medlar A, et al. Risk HLA-DQA1 and PLA(2)R1 alleles in idiopathic membranous nephropathy. N Engl J Med 2011; 364:616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19306/abstract/44\">",
"      Comparison of idiopathic and systemic lupus erythematosus-associated membranous glomerulonephropathy in children. The Southwest Pediatric Nephrology Study Group. Am J Kidney Dis 1986; 7:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19306/abstract/45\">",
"      Nagahama K, Matsushita H, Hara M, et al. Bucillamine induces membranous glomerulonephritis. Am J Kidney Dis 2002; 39:706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19306/abstract/46\">",
"      Hoshino J, Ubara Y, Hara S, et al. Outcome and treatment of bucillamine-induced nephropathy. Nephron Clin Pract 2006; 104:c15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19306/abstract/47\">",
"      Stokes MB, Foster K, Markowitz GS, et al. Development of glomerulonephritis during anti-TNF-alpha therapy for rheumatoid arthritis. Nephrol Dial Transplant 2005; 20:1400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19306/abstract/48\">",
"      Chin G, Luxton G, Harvey JM. Infliximab and nephrotic syndrome. Nephrol Dial Transplant 2005; 20:2824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19306/abstract/49\">",
"      den Broeder AA, Assmann KJ, van Riel PL, Wetzels JF. Nephrotic syndrome as a complication of anti-TNFalpha in a patient with rheumatoid arthritis. Neth J Med 2003; 61:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19306/abstract/50\">",
"      Hall CL, Jawad S, Harrison PR, et al. Natural course of penicillamine nephropathy: a long term study of 33 patients. Br Med J (Clin Res Ed) 1988; 296:1083.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19306/abstract/51\">",
"      Hall CL, Fothergill NJ, Blackwell MM, et al. The natural course of gold nephropathy: long term study of 21 patients. Br Med J (Clin Res Ed) 1987; 295:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19306/abstract/52\">",
"      Katz WA, Blodgett RC Jr, Pietrusko RG. Proteinuria in gold-treated rheumatoid arthritis. Ann Intern Med 1984; 101:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19306/abstract/53\">",
"      Lindell A, Denneberg T, Enestr&ouml;m S, et al. Membranous glomerulonephritis induced by 2-mercaptopropionylglycine (2-MPG). Clin Nephrol 1990; 34:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19306/abstract/54\">",
"      Romagnoli P, Spinas GA, Sinigaglia F. Gold-specific T cells in rheumatoid arthritis patients treated with gold. J Clin Invest 1992; 89:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19306/abstract/55\">",
"      Tournade H, Guery JC, Pasquier R, et al. Experimental gold-induced autoimmunity. Nephrol Dial Transplant 1991; 6:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19306/abstract/56\">",
"      Gunnarsson I, Ringertz B, Bratt J, Sundelin B. HLA-DRB1*0301 and DQA1*0501 in RA. Ann Rheum Dis 2001; 60:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19306/abstract/57\">",
"      Radford MG Jr, Holley KE, Grande JP, et al. Reversible membranous nephropathy associated with the use of nonsteroidal anti-inflammatory drugs. JAMA 1996; 276:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19306/abstract/58\">",
"      Campistol JM, Galofre J, Botey A, et al. Reversible membranous nephritis associated with diclofenac. Nephrol Dial Transplant 1989; 4:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19306/abstract/59\">",
"      Markowitz GS, Falkowitz DC, Isom R, et al. Membranous glomerulopathy and acute interstitial nephritis following treatment with celecoxib. Clin Nephrol 2003; 59:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19306/abstract/60\">",
"      Lai KN, Li PK, Lui SF, et al. Membranous nephropathy related to hepatitis B virus in adults. N Engl J Med 1991; 324:1457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19306/abstract/61\">",
"      Yoshikawa N, Ito H, Yamada Y, et al. Membranous glomerulonephritis associated with hepatitis B antigen in children: a comparison with idiopathic membranous glomerulonephritis. Clin Nephrol 1985; 23:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19306/abstract/62\">",
"      Lin CY, Lo SC. Treatment of hepatitis B virus-associated membranous nephropathy with adenine arabinoside and thymic extract. Kidney Int 1991; 39:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19306/abstract/63\">",
"      Seggie J, Davies PG, Ninin D, Henry J. Patterns of glomerulonephritis in Zimbabwe: survey of disease characterised by nephrotic proteinuria. Q J Med 1984; 53:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19306/abstract/64\">",
"      Stehman-Breen C, Alpers CE, Couser WG, et al. Hepatitis C virus associated membranous glomerulonephritis. Clin Nephrol 1995; 44:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19306/abstract/65\">",
"      Burstein DM, Korbet SM, Schwartz MM. Membranous glomerulonephritis and malignancy. Am J Kidney Dis 1993; 22:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19306/abstract/66\">",
"      Hill PA, Goodman DG, Snyder RD. Nephrotic syndrome associated with carcinoma of the breast. Clin Nephrol 2003; 60:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19306/abstract/67\">",
"      Ronco PM. Paraneoplastic glomerulopathies: new insights into an old entity. Kidney Int 1999; 56:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19306/abstract/68\">",
"      Da'as N, Polliack A, Cohen Y, et al. Kidney involvement and renal manifestations in non-Hodgkin's lymphoma and lymphocytic leukemia: a retrospective study in 700 patients. Eur J Haematol 2001; 67:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19306/abstract/69\">",
"      Rihova Z, Honsova E, Merta M, et al. Secondary membranous nephropathy--one center experience. Ren Fail 2005; 27:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19306/abstract/70\">",
"      Cahen R, Francois B, Trolliet P, et al. Aetiology of membranous glomerulonephritis: a prospective study of 82 adult patients. Nephrol Dial Transplant 1989; 4:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19306/abstract/71\">",
"      Lefaucheur C, Stengel B, Nochy D, et al. Membranous nephropathy and cancer: Epidemiologic evidence and determinants of high-risk cancer association. Kidney Int 2006; 70:1510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19306/abstract/72\">",
"      Bj&oslash;rneklett R, Vikse BE, Svarstad E, et al. Long-term risk of cancer in membranous nephropathy patients. Am J Kidney Dis 2007; 50:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19306/abstract/73\">",
"      Couser WG, Wagonfeld JB, Spargo BH, Lewis EJ. Glomerular deposition of tumor antigen in membranous nephropathy associated with colonic carcinoma. Am J Med 1974; 57:962.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19306/abstract/74\">",
"      Wakashin M, Wakashin Y, Iesato K, et al. Association of gastric cancer and nephrotic syndrome. An immunologic study in three patients. Gastroenterology 1980; 78:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19306/abstract/75\">",
"      Kerpen HO, Bhat JG, Feiner HD, Baldwin DS. Membranes nephropathy associated with renal cell carcinoma. Evidence against a role of renal tubular or tumor antibodies in pathogenesis. Am J Med 1978; 64:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19306/abstract/76\">",
"      Togawa A, Yamamoto T, Suzuki H, et al. Membranous glomerulonephritis associated with renal cell carcinoma: failure to detect a nephritogenic tumor antigen. Nephron 2002; 90:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19306/abstract/77\">",
"      Gamble CN, Reardan JB. Immunopathogenesis of syphilitic glomerulonephritis. Elution of antitreponemal antibody from glomerular immune-complex deposits. N Engl J Med 1975; 292:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19306/abstract/78\">",
"      O'Regan S, Fong JS, de Chadar&eacute;vian JP, et al. Treponemal antigens in congenital and acquired syphilitic nephritis: demonstration by immunofluorescence studies. Ann Intern Med 1976; 85:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19306/abstract/79\">",
"      Hunte W, al-Ghraoui F, Cohen RJ. Secondary syphilis and the nephrotic syndrome. J Am Soc Nephrol 1993; 3:1351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19306/abstract/80\">",
"      Losito A, Bucciarelli E, Massi-Benedetti F, Lato M. Membranous glomerulonephritis in congenital syphilis. Clin Nephrol 1979; 12:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19306/abstract/81\">",
"      Yuceoglu AM, Sagel I, Tresser G, et al. The glomerulopathy of congenital syphilis. A curable immune-deposit disease. JAMA 1974; 229:1085.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19306/abstract/82\">",
"      Alexander MP, Larsen CP, Gibson IW, et al. Membranous glomerulonephritis is a manifestation of IgG4-related disease. Kidney Int 2013; 83:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19306/abstract/83\">",
"      Saeki T, Imai N, Ito T, et al. Membranous nephropathy associated with IgG4-related systemic disease and without autoimmune pancreatitis. Clin Nephrol 2009; 71:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19306/abstract/84\">",
"      Jindal N, Yadav D, Passero C, et al. Membranous nephropathy: a rare renal manifestation of IgG4-related systemic disease. Clin Nephrol 2012; 77:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19306/abstract/85\">",
"      Cravedi P, Abbate M, Gagliardini E, et al. Membranous nephropathy associated with IgG4-related disease. Am J Kidney Dis 2011; 58:272.",
"     </a>",
"    </li>",
"    <li>",
"     Couser, WG, Alpers, CE. Membranous nephropathy. In: Immunologic Renal Diseases, 2 ed, Neilson, EG, Couser, WG (Eds), Lippincott Williams and Wilkins, Philadelphia 2001. p. 1030.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19306/abstract/87\">",
"      Breysse P, Couser WG, Alpers CE, et al. Membranous nephropathy and formaldehyde exposure. Ann Intern Med 1994; 120:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19306/abstract/88\">",
"      Wakai S, Magil AB. Focal glomerulosclerosis in idiopathic membranous glomerulonephritis. Kidney Int 1992; 41:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19306/abstract/89\">",
"      Dumoulin A, Hill GS, Montseny JJ, Meyrier A. Clinical and morphological prognostic factors in membranous nephropathy: significance of focal segmental glomerulosclerosis. Am J Kidney Dis 2003; 41:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19306/abstract/90\">",
"      Bertani T, Appel GB, D'Agati V, et al. Focal segmental membranous glomerulonephropathy associated with other glomerular diseases. Am J Kidney Dis 1983; 2:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19306/abstract/91\">",
"      Furuta T, Seino J, Saito T, et al. Insulin deposits in membranous nephropathy associated with diabetes mellitus. Clin Nephrol 1992; 37:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19306/abstract/92\">",
"      Tse WY, Howie AJ, Adu D, et al. Association of vasculitic glomerulonephritis with membranous nephropathy: a report of 10 cases. Nephrol Dial Transplant 1997; 12:1017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19306/abstract/93\">",
"      James SH, Lien YH, Ruffenach SJ, Wilcox GE. Acute renal failure in membranous glomerulonephropathy: a result of superimposed crescentic glomerulonephritis. J Am Soc Nephrol 1995; 6:1541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19306/abstract/94\">",
"      Sano T, Kamata K, Shigematsu H, Kobayashi Y. A case of anti-glomerular basement membrane glomerulonephritis superimposed on membranous nephropathy. Nephrol Dial Transplant 2000; 15:1238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19306/abstract/95\">",
"      Dwyer KM, Agar JW, Hill PA, Murphy BF. Membranous nephropathy and anti-neutrophil cytoplasmic antibody-associated glomerulonephritis: a report of 2 cases. Clin Nephrol 2001; 56:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19306/abstract/96\">",
"      Nasr SH, Said SM, Valeri AM, et al. Membranous glomerulonephritis with ANCA-associated necrotizing and crescentic glomerulonephritis. Clin J Am Soc Nephrol 2009; 4:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19306/abstract/97\">",
"      Nasr SH, Ilamathi ME, Markowitz GS, D'Agati VD. A dual pattern of immunofluorescence positivity. Am J Kidney Dis 2003; 42:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19306/abstract/98\">",
"      Marshall S, Dressler R, D'Agati V. Membranous lupus nephritis with antineutrophil cytoplasmic antibody-associated segmental necrotizing and crescentic glomerulonephritis. Am J Kidney Dis 1997; 29:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19306/abstract/99\">",
"      Surindran S, Ayalon R, Hasan N, et al. Co-existence of ANCA-associated glomerulonephritis and anti-phospholipase A2 receptor antibody positive membranous nephropathy. Clinical Kidney Journal 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/54/19306/abstract/100\">",
"      Hladunewich MA, Troyanov S, Calafati J, et al. The natural history of the non-nephrotic membranous nephropathy patient. Clin J Am Soc Nephrol 2009; 4:1417.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3050 Version 16.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-213.134.24.46-82D89F4E57-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_54_19306=[""].join("\n");
var outline_f18_54_19306=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H26\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Idiopathic versus secondary MN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Animal models",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Phospholipase A2 receptor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Neutral endopeptidase",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5350192\">",
"      Intracellular antigens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H93126072\">",
"      Cationic bovine serum albumin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H93126080\">",
"      Other antigens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Role of T cells",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H61680974\">",
"      Genetic associations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Systemic lupus erythematosus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Drugs, particularly penicillamine and gold",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Nonsteroidal antiinflammatory drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Hepatitis B virus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Hepatitis C virus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Malignancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4189223\">",
"      Syphilis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4662280\">",
"      IgG4-related disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Hematopoietic cell transplantation and graft-versus-host-disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Kidney transplant",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Others",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      MEMBRANOUS NEPHROPATHY WITH OTHER GLOMERULAR DISEASES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Crescentic glomerulonephritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Screening for malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/3050\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/3050|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?30/50/31533\" title=\"figure 1\">",
"      Natural history of MN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/3050|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?16/16/16649\" title=\"picture 1A\">",
"      Membranous Light",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?27/42/28321\" title=\"picture 1B\">",
"      Membranous IF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?38/46/39656\" title=\"picture 1C\">",
"      Membranous EM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?24/54/25445\" title=\"picture 1D\">",
"      Membranous Silver",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?32/5/32856\" title=\"picture 1E\">",
"      Membranous EM II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?38/39/39543\" title=\"picture 1F\">",
"      SLE Membranous EM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/3050|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/6/14443\" title=\"table 1\">",
"      Causes membranous nephropathy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/10/18598?source=related_link\">",
"      Acute kidney injury (acute renal failure) in minimal change disease and other forms of nephrotic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/39/12918?source=related_link\">",
"      Alternative agents in the treatment of idiopathic membranous nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/36/27209?source=related_link\">",
"      Clinical manifestations and diagnosis of acute interstitial nephritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/25/23962?source=related_link\">",
"      Clinical manifestations, diagnosis, and grading of chronic graft-versus-host disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/19/1337?source=related_link\">",
"      Clinical presentation and diagnosis of IgA nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/62/25577?source=related_link\">",
"      Cystine stones",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/3/27706?source=related_link\">",
"      Diagnosis and classification of renal disease in systemic lupus erythematosus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/16/3338?source=related_link\">",
"      Diagnosis and differential diagnosis of systemic lupus erythematosus in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/31/27130?source=related_link\">",
"      Differential diagnosis and evaluation of glomerular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/6/41066?source=related_link\">",
"      Epidemiology, classification, and pathogenesis of focal segmental glomerulosclerosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/50/34601?source=related_link\">",
"      Etiology, clinical features, and diagnosis of minimal change disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/36/1609?source=related_link\">",
"      Kidney disease following hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/41/33430?source=related_link\">",
"      Lipid abnormalities in nephrotic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/30/18921?source=related_link\">",
"      Mechanisms of immune injury of the glomerulus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/18/34088?source=related_link\">",
"      Membranous nephropathy and renal transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/0/24582?source=related_link\">",
"      NSAIDs: Acute kidney injury (acute renal failure) and nephrotic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/55/13178?source=related_link\">",
"      Overview of IgG4-related disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/19/3384?source=related_link\">",
"      Overview of biologic agents in the rheumatic diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/18/32041?source=related_link\">",
"      Overview of heavy proteinuria and the nephrotic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/32/18954?source=related_link\">",
"      Overview of the systemic and nonarticular manifestations of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/9/37017?source=related_link\">",
"      Pathogenesis, clinical manifestations, and treatment of early syphilis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/28/44488?source=related_link\">",
"      Renal disease associated with hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/30/37353?source=related_link\">",
"      Renal disease associated with hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/12/20677?source=related_link\">",
"      Renal disease in Sj&ouml;gren's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/31/40438?source=related_link\">",
"      Renal disease in sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/12/3273?source=related_link\">",
"      Renal vein thrombosis and hypercoagulable state in nephrotic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/28/34243?source=related_link\">",
"      Schistosomiasis and glomerular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/58/6056?source=related_link\">",
"      The adaptive cellular immune response",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/41/37530?source=related_link\">",
"      Treatment of idiopathic membranous nephropathy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_54_19307="Tumor embolism malignancies";
var content_f18_54_19307=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F67921&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F67921&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Malignancies associated with tumor embolism",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Renal cell",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hepatocellular",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Breast",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gastric",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prostate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Choriocarcinoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Colorectal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cervical",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mesothelioma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ovarian",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bladder",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Skin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pancreatic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lung",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Parotid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Thyroid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Atrial myxoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Wilms' tumor",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from Roberts, KE, et al. Am J Med 2003; 115:228.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_54_19307=[""].join("\n");
var outline_f18_54_19307=null;
var title_f18_54_19308="ABCD2 score";
var content_f18_54_19308=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F62381&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F62381&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    ABCD",
"    <sup>",
"     2",
"    </sup>",
"    score",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td colspan=\"2\">",
"        The ABCD",
"        <sup>",
"         2",
"        </sup>",
"        score can be used to estimate the risk of ischemic stroke in the first two days after TIA. The score is tallied as follows:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"2\">",
"        Age:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &ge;60 years",
"       </td>",
"       <td>",
"        1 point",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &lt;60 years",
"       </td>",
"       <td>",
"        0 points",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"2\">",
"        Blood pressure elevation when first assessed after TIA:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Systolic &ge;140 mmHg",
"        <strong>",
"         or",
"        </strong>",
"        diastolic &ge;90 mmHg",
"       </td>",
"       <td>",
"        1 point",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Systolic &lt;140 mmHg",
"        <strong>",
"         and",
"        </strong>",
"        diastolic &lt;90 mmHg",
"       </td>",
"       <td>",
"        0 points",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"2\">",
"        Clinical features:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Unilateral weakness",
"       </td>",
"       <td>",
"        2 points",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Isolated speech disturbance",
"       </td>",
"       <td>",
"        1 point",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Other",
"       </td>",
"       <td>",
"        0 points",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"2\">",
"        Duration of TIA symptoms:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &ge;60 minutes",
"       </td>",
"       <td>",
"        2 points",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        10 to 59 minutes",
"       </td>",
"       <td>",
"        1 point",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &lt;10 minutes",
"       </td>",
"       <td>",
"        0 points",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"2\">",
"        Diabetes:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Present",
"       </td>",
"       <td>",
"        1 point",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Absent",
"       </td>",
"       <td>",
"        0 points",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Johnston SC, Rothwell PM, Nguyen-Huynh MN, et al. Validation and refinement of scores to predict very early stroke risk after transient ischaemic attack. Lancet 2007; 369:283.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_54_19308=[""].join("\n");
var outline_f18_54_19308=null;
var title_f18_54_19309="Allopurinol hyperuricosuria";
var content_f18_54_19309=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F80273&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F80273&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Allopurinol prevents stones in hyperuricosuria",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 413px; height: 241px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    When compared to placebo, allopurinol protects against new stone formation in hyperuricosuric calcium oxalate stone formers.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Ettinger, B, Tang, A, Citron, JT, et al, N Engl J Med 1986; 315:1386.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_54_19309=[""].join("\n");
var outline_f18_54_19309=null;
var title_f18_54_19310="Neuroblastoma incidence by age";
var content_f18_54_19310=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F72658&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F72658&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 502px\">",
"   <div class=\"ttl\">",
"    Age-specific neuroblastoma incidence rates by sex, all races, SEER 1976-84 and 1986-94",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 482px; height: 544px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From Goodman, MT, Gurney, JG, Smith, MA, Olshan, AF. Sympathetic nervous system tumors. In: Cancer Incidence and Survival Among Children and Adolescents: United States SEER Program 1975-1995, Ries, LA, Smith, MA, Gurney, JG, et al, National Cancer Institute, SEER Program. NIH Pub No. 99-4649; Bethesda, MD 1999. p. 66-67.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_54_19310=[""].join("\n");
var outline_f18_54_19310=null;
var title_f18_54_19311="Fetal station";
var content_f18_54_19311=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F67068&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F67068&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Assessing descent of the fetal head by vaginal examination",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 400px; height: 272px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The fetus is at -2 station signifying that the leading bony edge of the presenting part is two centimeters above the ischial spines. The head is engaged at 0 station.",
"    <div class=\"footnotes\">",
"     Sp: ischial spine.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_54_19311=[""].join("\n");
var outline_f18_54_19311=null;
